<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">86972</article-id><article-id pub-id-type="doi">10.7554/eLife.86972</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.86972.2</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Importance of glutamine in synaptic vesicles revealed by functional studies of <italic>SLC6A17</italic> and its mutations pathogenic for intellectual disability</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-307057"><name><surname>Jia</surname><given-names>Xiaobo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4214-8906</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-307103"><name><surname>Zhu</surname><given-names>Jiemin</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-307104"><name><surname>Bian</surname><given-names>Xiling</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307105"><name><surname>Liu</surname><given-names>Sulin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6776-2216</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307106"><name><surname>Yu</surname><given-names>Sihan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307107"><name><surname>Liang</surname><given-names>Wenjun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307108"><name><surname>Jiang</surname><given-names>Lifen</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-307109"><name><surname>Mao</surname><given-names>Renbo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-246279"><name><surname>Zhang</surname><given-names>Wenxia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-2641"><name><surname>Rao</surname><given-names>Yi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0405-5426</contrib-id><email>yrao@pku.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="fn1">‡</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/029819q61</institution-id><institution>Chinese Institute for Brain Research</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Changping Laboratory</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02drdmm93</institution-id><institution>Research Unit of Medical Neurobiology, Chinese Academy of Medical Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02v51f717</institution-id><institution>Laboratory of Neurochemical Biology, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, School of Life Sciences, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, School of Chemistry and Chemical Engineering, Peking University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00sdcjz77</institution-id><institution>Institute of Molecular Physiology, Shenzhen Bay Laboratory</institution></institution-wrap><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013xs5b60</institution-id><institution>Capital Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Brose</surname><given-names>Nils</given-names></name><role>Reviewing Editor</role><aff><institution>Max Planck Institute of Experimental Medicine</institution><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Behrens</surname><given-names>Timothy E</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="other" id="fn1"><label>‡</label><p>Lead contact</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>13</day><month>07</month><year>2023</year></pub-date><volume>12</volume><elocation-id>RP86972</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-02-18"><day>18</day><month>02</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-02-15"><day>15</day><month>02</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.25.513688"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-04-05"><day>05</day><month>04</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.86972.1"/></event></pub-history><permissions><copyright-statement>© 2023, Jia, Zhu, Bian et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Jia, Zhu, Bian et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-86972-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-86972-figures-v1.pdf"/><abstract><p>Human mutations in the gene encoding the solute carrier (SLC) 6A17 caused intellectual disability (ID). The physiological role of <italic>SLC6A17</italic> and pathogenesis of <italic>SLC6A17</italic>-based-ID were both unclear. Here, we report learning deficits in <italic>Slc6a17</italic> knockout and point mutant mice. Biochemistry, proteomic, and electron microscopy (EM) support SLC6A17 protein localization in synaptic vesicles (SVs). Chemical analysis of SVs by liquid chromatography coupled to mass spectrometry (LC-MS) revealed glutamine (Gln) in SVs containing SLC6A17. Virally mediated overexpression of SLC6A17 increased Gln in SVs. Either genetic or virally mediated targeting of <italic>Slc6a17</italic> reduced Gln in SVs. One ID mutation caused SLC6A17 mislocalization while the other caused defective Gln transport. Multidisciplinary approaches with seven types of genetically modified mice have shown Gln as an endogenous substrate of SLC6A17, uncovered Gln as a new molecule in SVs, established the necessary and sufficient roles of SLC6A17 in Gln transport into SVs, and suggested SV Gln decrease as the key pathogenetic mechanism in human ID.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SLC6A17</kwd><kwd>learning</kwd><kwd>memory</kwd><kwd>glutamine</kwd><kwd>synaptic vesicle</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Chinese Institute for Brain Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rao</surname><given-names>Yi</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Peking-Tsinghua Center for Life Science</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rao</surname><given-names>Yi</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100021177</institution-id><institution>Shenzhen Bay Laboratory</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rao</surname><given-names>Yi</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100019018</institution-id><institution>Chinese Academy of Medical Sciences Initiative for Innovative Medicine</institution></institution-wrap></funding-source><award-id>2019-I2M-5-015</award-id><principal-award-recipient><name><surname>Rao</surname><given-names>Yi</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Changping laboratory</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rao</surname><given-names>Yi</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Physiological studies of SLC6A17 and its pathogenic mutations revealed that glutamine is transported into synaptic vesicles (SVs) in an SLC6A17-dependent manner and all pathogenic conditions reduced glutamine level in SVs.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>With an approximate prevalence of 1%, intellectual disability (ID) in humans is a neurodevelopmental disorder with debilitating effects on patients (<xref ref-type="bibr" rid="bib73">Maulik et al., 2011</xref>). Molecular genetic research into ID has identified multiple genes whose defects are underlying ID (<xref ref-type="bibr" rid="bib27">de Ligt et al., 2012</xref>; <xref ref-type="bibr" rid="bib34">Gilissen et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Hamdan et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Hu et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Khan et al., 2016</xref>; <xref ref-type="bibr" rid="bib58">Lelieveld et al., 2016</xref>; <xref ref-type="bibr" rid="bib88">Rauch et al., 2012</xref>; <xref ref-type="bibr" rid="bib92">Ropers, 2010</xref>; <xref ref-type="bibr" rid="bib104">Vissers et al., 2016</xref>). Functional studies of products encoded by these genes are essential for our mechanistic understanding of ID pathogenesis.</p><p>Mutations causing ID were found in the gene encoding SLC6A17 (<xref ref-type="bibr" rid="bib47">Iqbal et al., 2015</xref>; <xref ref-type="bibr" rid="bib105">Waltl, 2015</xref>). SLC6A17, also known as Rxt1, NTT4, XT1, or B<sup>0</sup>AT3 (<xref ref-type="bibr" rid="bib29">el Mestikawy et al., 1994</xref>; <xref ref-type="bibr" rid="bib61">Liu et al., 1993</xref>), was discovered 30 years ago (<xref ref-type="bibr" rid="bib29">el Mestikawy et al., 1994</xref>; <xref ref-type="bibr" rid="bib61">Liu et al., 1993</xref>). It is predominantly expressed in the nervous system (<xref ref-type="bibr" rid="bib29">el Mestikawy et al., 1994</xref>; <xref ref-type="bibr" rid="bib32">Fischer et al., 1999</xref>; <xref ref-type="bibr" rid="bib39">Hägglund et al., 2013</xref>; <xref ref-type="bibr" rid="bib49">Jursky and Nelson, 1999</xref>; <xref ref-type="bibr" rid="bib50">Kachidian et al., 1999</xref>; <xref ref-type="bibr" rid="bib65">Luque et al., 1996</xref>; <xref ref-type="bibr" rid="bib71">Masson et al., 1995</xref>; <xref ref-type="bibr" rid="bib72">Masson et al., 1999</xref>). SLC6A17 protein was localized on synaptic vesicles (SVs) (<xref ref-type="bibr" rid="bib32">Fischer et al., 1999</xref>; <xref ref-type="bibr" rid="bib50">Kachidian et al., 1999</xref>; <xref ref-type="bibr" rid="bib72">Masson et al., 1999</xref>). Those facts, together with its membership in the SLC6 or the neurotransmitter transporter (NTT) family, suggest that SLC6A17 could be a vesicular transporter for a neurotransmitter(s).</p><p>Early efforts failed to identify substrates transported by SLC6A17 (<xref ref-type="bibr" rid="bib14">Bröer, 2006</xref>; <xref ref-type="bibr" rid="bib29">el Mestikawy et al., 1994</xref>; <xref ref-type="bibr" rid="bib61">Liu et al., 1993</xref>). A later study using pheochromocytoma (PC)12 cells and <italic>SLC6A17</italic>-tranfected Chinese hamster ovary (CHO) cells found that SLC6A17 could transport four amino acids (AA): proline (Pro), glycine (Gly), leucine (Leu), and alanine (Ala) (<xref ref-type="bibr" rid="bib80">Parra et al., 2008</xref>). Another study using human embryonic kidney (HEK) cells reported transport of nine AAs: Leu, methionine (Met), Pro, cysteine (Cys), Ala, glutamine (Gln), serine (Ser), histidine (His), and Gly (<xref ref-type="bibr" rid="bib111">Zaia and Reimer, 2009</xref>). There are three differences between these two studies: that the second study reported five more AAs (Met, Cys, Gln, Ser, and His) as substrates of SLC6A17, that the second study used modified SLC6A17 to facilitate its membrane localization (<xref ref-type="bibr" rid="bib111">Zaia and Reimer, 2009</xref>), and that one reported Na<sup>+</sup> dependence (<xref ref-type="bibr" rid="bib111">Zaia and Reimer, 2009</xref>), whereas the other reported H<sup>+</sup> dependence (<xref ref-type="bibr" rid="bib80">Parra et al., 2008</xref>). However, none of these AAs have been found in the SVs. It remains unknown which of the four or nine AAs, if any, are present in the SVs in an SLC6A17-dependent manner in vivo.</p><p>Thus, how mutations in a single AA of SLC6A17 lead to ID is unknown, the substrate(s) physiologically transported by SLC6A17 is unknown, and behavioral phenotypes of animals lacking <italic>Slc6a17</italic> or carrying any mutation pathogenic in human patients have not been characterized.</p><p>We have now generated mouse mutants either lacking the <italic>Slc6a17</italic> gene or mimicking a point mutation found in ID patients. They had similar phenotypes including deficient learning and memory, indicating that the human mutation was a loss-of-function (LOF) mutation. These are the first animal models of ID caused by <italic>Slc6a17</italic> mutations. While two in vitro studies with cell lines suggested that SLC6A17 could transport up to nine neutral AAs, we could only find that Gln was present in the SVs. From multiple gain-of-function (GOF) and LOF experiments, we have obtained evidence that SLC6A17 is not only sufficient for Gln presence in the SVs in vivo, but it is also physiologically necessary for Gln presence in the SVs. Thus, we have found the endogenous substrate for SLC6A17. Of the two known human mutations pathogenic for ID (<xref ref-type="bibr" rid="bib47">Iqbal et al., 2015</xref>), we provide evidence that one caused the SLC6A17 to be mislocalized subcellularly and the other, while still on SVs, was defective in Gln transport. Decreases in Gln in SVs caused by SLC6A17 mutations were not correlated with any decrease in glutamate (Glu) or gamma-aminobutyric acid (GABA), dissociating vesicular Gln from the Glu/GABA-Gln cycle between neurons and glia. In addition to dissecting the molecular mechanisms underlying ID caused by <italic>Slc6a17</italic> mutations, we report for the first time that Gln is robustly and reproducibly detected in the SVs, which should stimulate further research into its potential roles in neurotransmission.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Pattern of <italic>Slc6a17</italic> expression</title><p>To examine the pattern of <italic>Slc6a17</italic> expression, we designed a knock-in mouse line <italic>Slc6a17</italic><sup>-2A-CreERT2</sup> (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). These mice were generated by in-frame fusion of a T2A sequence (<xref ref-type="bibr" rid="bib2">Ahier and Jarriault, 2014</xref>; <xref ref-type="bibr" rid="bib25">Daniels et al., 2014</xref>; <xref ref-type="bibr" rid="bib101">Trichas et al., 2008</xref>) and CreERT2 (<xref ref-type="bibr" rid="bib31">Feil et al., 1996</xref>; <xref ref-type="bibr" rid="bib37">Gu et al., 1994</xref>; <xref ref-type="bibr" rid="bib46">Indra et al., 1999</xref>; <xref ref-type="bibr" rid="bib94">Sauer and Henderson, 1988</xref>) to the C terminus of <italic>Slc6a17</italic> with its stop codon removed (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). We crossed the <italic>Slc6a17</italic><sup>-2A-CreERT2</sup> mice with the Ai14 reporter line, which contained floxed stop-tdTomato (<xref ref-type="bibr" rid="bib68">Madisen et al., 2010</xref>). Treatment with tamoxifen removed the stop codon and thus allowed specific expression of tdTomato in <italic>Slc6a17</italic>-positive cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Labeled cells were exclusively neuronal with no glial expression detected.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Slc6a17</italic> expression in the mouse brain.</title><p>(<bold>A</bold>) A schematic diagram illustrating the strategy for the generation of <italic>Slc6a17</italic><sup>-2A-CreERT2</sup> mice. Crossing of <italic>Slc6a17</italic><sup>-2A-CreERT2</sup> mice with Ai14 (LSL-tdTomato) mice allowed specific labeling of <italic>Slc6a17</italic>-expressing neuron after tamoxifen injection. More details in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>. (<bold>B–I</bold>) Representative coronal sections of <italic>Slc6a17</italic><sup>-2A-CreERT2</sup>::Ai14 mice. Numbers above images indicate the anteroposterior position of the section from Bregma in millimeters (mm), based on <xref ref-type="bibr" rid="bib81">Paxinos and Franklin, 2019</xref>. Scale bars = 1 mm. (<bold>J</bold>) <italic>Slc6a17</italic>-positive neurons in the basolateral amygdaloid nucleus (BLA) and the central amygdaloid nucleus (CeA). Scale bars = 100 μm. (<bold>K</bold>) Hippocampal expression of <italic>Slc6a17. Slc6a17</italic>-positive neurons are densely distributed in the granule cell layer of the dentate gyrus (GrDG), and CA3, with little expression in the CA1 and the CA2. Scale bars = 200 μm. Abbreviations: 2Cb, lobule 2 of the cerebellar vermis; 3Cb, lobule 3 of the cerebellar vermis; 4/5Cb, lobule 4 and 5 of the cerebellar vermis; AON, accessory olfactory nucleus; AM, anteromedial thalamic nucleus; AV, anteroventral thalamic nucleus; BLA, basolateral amygdaloid nucleus; Ent, entorhinal cortex; CB, cerebellum; Cg1/2, cingulate ccortex; CIC, central nucleus of the inferior colliculus; Ctx, cortex; Hip, hippocampus; LO, lateral orbital cortex; LS, lateral septal nucleus; M1, primary motor cortex; M2, secondary motor cortex; OB, main olfactory bulb; Pir, piriform cortex; Pn, pontine nuclei; Rt, reticular thalamic nucleus; S1, primary somatosensory cortex; S2, secondary somatosensory cortex; SCN, suprachiasmatic nucleus; SFO, subfornical organ; SuG, superficial gray layer of superior colliculus; Sim, simple lobule; Th, thalamus; V1, primary visual cortex; V2, secondary visual cortex; VPM, ventral posteromedial nucleus.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Generation of <italic>Slc6a17</italic> knock-in mice.</title><p>(<bold>A</bold>) A schematic diagram illustrating the knock-in strategy for generating <italic>Slc6a17</italic><sup>-2A-CreERT2</sup> KI mice. This CRISPR/Cas9-mediated strategy allowed CreERT2 to be co-expressed with SLC6A17 protein fused in frame with a T2A sequence. Crossing <italic>Slc6a17</italic><sup>-2A-CreERT2</sup> mice with Ai14 (LSL-tdTomato) mice specifically labeled <italic>Slc6a17</italic>-expressing cells after tamoxifen injection. (<bold>B, C</bold>) Representative sagittal sections of <italic>Slc6a17</italic><sup>-2A-CreERT2</sup>::Ai14 mouse brains at postnatal day 56. Scale bars = 1 mm. (<bold>D</bold>) A schematic diagram illustrating the knock-in strategy for generating <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> KI mice. <italic>Slc6a17</italic> was fused in-frame with 3 repeats of the HA tag, T2A, and iCre.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig1-figsupp1-v1.tif"/></fig></fig-group><p><italic>Slc6a17</italic> expression was found in the neocortex, the thalamus, the amygdala, the hippocampus, the pontine nuclei, and the brainstem (<xref ref-type="fig" rid="fig1">Figure 1B–K</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B, C</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Strong expression of <italic>Slc6a17</italic> was detected in the dentate gyrus (DG) and the CA3 region of the hippocampus (<xref ref-type="fig" rid="fig1">Figure 1K</xref>), which is essential for spatial learning and memory. Little expression was observed in either CA1 or CA2 (<xref ref-type="fig" rid="fig1">Figure 1K</xref>). <italic>Slc6a17</italic> was also expressed in the basolateral amygdala (BLA) (<xref ref-type="fig" rid="fig1">Figure 1J</xref>), a brain area essential for emotion and fear learning.</p></sec><sec id="s2-2"><title>Behavioral deficits of <italic>Slc6a17</italic> mutant mice</title><p>To investigate the functional role of <italic>Slc6a17</italic>, we generated a knock-out (KO) mouse mutant line with exon 2 deleted from the <italic>Slc6a17</italic> gene (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). These <italic>Slc6a17</italic>-KO mice were not significantly different from the wild type (WT, <italic>Slc6a17</italic><sup>+/+</sup>) mice in body weight (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), basal activities (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>), or short-term memory (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Slc6a17</italic>-KO mice exhibited impaired memory formation.</title><p>(<bold>A</bold>) A schematic diagram illustrating the knock-out strategy for generating <italic>Slc6a17</italic>-KO mice by CRISPR/Cas9. Exon 2 encoding the first 99 amino acids of <italic>Slc6a17</italic> was deleted. More details in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>. (<bold>B</bold>) A diagram of experiments for contextual and cued fear conditioning (n = 16, 23, and 18 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>+/-</sup>, and <italic>Slc6a17</italic><sup>-/-</sup>, respectively). Detailed description in ‘Experimental procedures.’ (<bold>C</bold>) <italic>Slc6a17</italic><sup>-/-</sup> mice exhibited a significant decrease in freezing behavior in both cued and contextual fear conditioning (day 2 context a, p=0.0062 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p&lt;0.0001 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>; Day 3 tone, p=0.0093 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.0012 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>). (<bold>D</bold>) A diagram of experiments for modified Morris water maze task (n = 15, 18, and 16 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>+/-</sup>, and <italic>Slc6a17</italic><sup>-/-</sup>, respectively). Detailed description in ‘Experimental procedures.’ (<bold>E</bold>) Latency to find the hidden platform during the training session. <italic>Slc6a17</italic><sup>-/-</sup> mice differed significantly from <italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>+/-</sup> mice (two-way ANOVA; main effect of training day: F (4.681, 210.7) = 46.55, p&lt;0.0001; main effect of genotype: F (2, 45) = 21.53, p&lt;0.0001; main effect of training day × genotype: F (12, 270) = 3.762, p&lt;0.0001; Tukey’s multiple comparisons test: day 2, p=0.0004 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.0002 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>; day 5, p=0.0002 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.008 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>; day 6, p=0.0002 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.0027 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>; day 7, p&lt;0.0001 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.0005 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>). (<bold>F</bold>) Representative swimming traces of each genotype. (<bold>G</bold>) Percentage of time spent in the target quadrant was significantly different (p=0.0004 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p&lt;0.0001 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>). (<bold>H</bold>) Number of crossings through the platform area was significantly different (p=0.0194 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.0054 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>). Here and hereafter, data in the figure are presented as the mean ± SEM, with * indicating p&lt;0.05, ** indicating p&lt;0.01, *** indicating p&lt;0.001, and **** indicating p&lt;0.0001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig2">Figure 2C, E, G, and H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Phenotypical analysis of <italic>Slc6a17</italic>-KO mice.</title><p>(<bold>A</bold>) <italic>Slc6a17</italic>-KO mice were not significantly different from the WT in body weight at the age of 10 wk, regardless of sex (male: n = 10, 16, and 8 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>+/-</sup>, and <italic>Slc6a17</italic><sup>-/-</sup>, respectively, p=0.8147 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.3456 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>; female: n = 13, 9, and 9 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>+/-</sup>, and <italic>Slc6a17</italic><sup>-/-</sup>, respectively, p&gt;0.9999 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.9896 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>). (<bold>B</bold>) Locomotor activities in the open field test were not significantly different among the three genotypes (n = 21, 26, and 17 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>+/-</sup>, and <italic>Slc6a17</italic><sup>-/-</sup>, respectively, p=0.0987 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.3233 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>). (<bold>C</bold>) Novel object recognition (NOR) was not significantly different among the three genotypes (n = 22, 22, and 20 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>+/-</sup>, and <italic>Slc6a17</italic><sup>-/-</sup>, respectively, p=0.9318 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.7978 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>). (<bold>D–F</bold>) <italic>Slc6a17</italic> KO mutants had lower levels of anxiety in elevated plus maze test (n = 33, 26, and 27 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>+/-</sup>, and <italic>Slc6a17</italic><sup>-/-</sup>, respectively): overall locomotion was not significantly different (<bold>D</bold>, p=0.3639 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.053 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); percentage of time spend in open arms was significantly increased in <italic>Slc6a17</italic><sup>-/-</sup> mice (<bold>E</bold>, p&lt;0.0001 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p&lt;0.0001 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); the travel distance in open arms was significantly increased in <italic>Slc6a17</italic><sup>-/-</sup> mice (p&lt;0.0001 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.0001 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Mass spectrometry (MS) analysis of <italic>Slc6a17</italic> KO mice.</title><p>TMT-labeled quantitative synaptic vesicle (SV) proteomics was performed in <italic>Slc6a17</italic>-KO mice. Briefly, SVs were immunoisolated from LP2 fraction of WT and <italic>Slc6a17</italic>-KO mice by anti-Syp. SV proteins from different samples were digested and then labeled separately by TMT regents (detailed description in ‘Experimental procedures’). Volcano plot showing SV proteins different between <italic>Slc6a17</italic><sup>-/-</sup> mice and <italic>Slc6a17</italic><sup>+/+</sup> mice. The y axis shows p-values in log<sub>10</sub> and the x axis shows the log<sub>2</sub> of the ratio of the level of a protein immunoisolated by anti-Syp from <italic>Slc6a17</italic><sup>-/-</sup> mice vs. that from <italic>Slc6a17</italic><sup>+/+</sup> mice. SLC6A17 was the only transporter significantly decreased in <italic>Slc6a17</italic>-KO mice. Known vesicular transporters are highlighted by blue cycles.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig2-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig2-figsupp2-v1.tif"/></fig></fig-group><p>To investigate learning and memory of <italic>Slc6a17</italic>-KO mice, we first tested <italic>Slc6a17</italic>-KO mice on a classical associative learning model of contextual and cued fear (<xref ref-type="bibr" rid="bib42">Hitti and Siegelbaum, 2014</xref>; <xref ref-type="bibr" rid="bib82">Phillips and LeDoux, 1992</xref>; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). Both the WT and the heterozygous (<italic>Slc6a17</italic><sup>+/-</sup>) mice spent a significant amount of time freezing (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) on day 2 in Context-a environment. However, homozygous (<italic>Slc6a17</italic><sup>-/-</sup>) mutants showed a dramatic decrease in freezing behavior compared to the other genotypes (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). On day 3, both <italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>+/-</sup> mice showed significantly increased freezing behavior (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), whereas <italic>Slc6a17</italic><sup>-/-</sup> mutants showed significant memory impairment in response to the tone (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). These results indicate that the <italic>Slc6a17</italic>-KO mice were severely deficient in contextual and cued fear memory.</p><p>We then tested hippocampus-dependent spatial learning and memory by evaluating the performance of mice in the Morris water maze (<xref ref-type="bibr" rid="bib76">Morris, 1984</xref>; <xref ref-type="bibr" rid="bib75">Morris et al., 1982</xref>; <xref ref-type="fig" rid="fig2">Figure 2D</xref>). During training, control (<italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>+/-</sup>) mice showed a gradually decreasing latency to find the platform in both visible and hidden sessions (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), whereas <italic>Slc6a17</italic><sup>-/-</sup> mutants exhibited significantly longer latency to find the platform (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Representative swimming traces of each genotype in probe trial are shown in <xref ref-type="fig" rid="fig2">Figure 2F</xref>. During the probe trial, control mice spent more time in the target quadrant (<xref ref-type="fig" rid="fig2">Figure 2F</xref>), whereas <italic>Slc6a17</italic><sup>-/-</sup> mutants spent much less time searching the platform quadrant (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>). The frequency that control animals crossed through the platform area was above chance level (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>), whereas <italic>Slc6a17</italic><sup>-/-</sup> mutants crossed the platform area much less than the other genotypes (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>).</p><p>Taken together, these data indicate that <italic>Slc6a17</italic>-KO mice are significantly impaired both in contextual and cued fear memory and in hippocampus-dependent spatial learning and memory.</p></sec><sec id="s2-3"><title>Behavioral deficits in <italic>Slc6a17</italic><sup>P663R</sup> mutant mice</title><p>We next generated a mouse line carrying a point mutation (P633R) found to be pathogenic in ID patients (<xref ref-type="bibr" rid="bib47">Iqbal et al., 2015</xref>). Three repeats of the hemagglutinin (HA) epitope (<xref ref-type="bibr" rid="bib54">Kolodziej and Young, 1991</xref>; ) and three repeats of the FLAG tag were fused in-frame to the C terminus of the endogenous P633R mutant (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Homozygous (<italic>Slc6a17</italic><sup>P633R/P633R</sup>) mutant mice were not significantly different from the WT (<italic>Slc6a17</italic><sup>+/+</sup>) or heterozygous (<italic>Slc6a17</italic><sup>P633R/+</sup>) in body weight (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>), basal activities (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>), or novel objection recognition (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Deficient memory in <italic>Slc6a17</italic><sup>P633R</sup> mice.</title><p>(<bold>A</bold>) A diagram illustrating the knock-in strategy for <italic>Slc6a17</italic> with a pathogenic point mutation (<italic>Slc6a17</italic><sup>P633R</sup>). It was tagged with three repeats of the HA epitope and three repeats of the FLAG epitope. More details in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>. (<bold>B</bold>) Immunocytochemistry of <italic>Slc6a17</italic><sup>P633R</sup> mouse brains with the anti-HA antibody showed that the subcellular localization of SLC6A17<sup>P633R</sup>-HA did not co-localized with synaptophysin. It was present in the cytoplasm. Representative view of CA3 is shown. Scale bar = 50 μm. (<bold>C</bold>) Experiments for contextual and cued fear conditioning (n = 17, 18, and 14 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>P633R/+</sup>, and <italic>Slc6a17</italic><sup>P633R/P633R</sup>, respectively). Detailed description in ‘Experimental procedures.’ (<bold>D</bold>) <italic>Slc6a17</italic><sup>P633R</sup> homozygous mutants exhibited significant decrease of freezing behavior in both cued and contextual fear conditioning (day 2 context A, p&lt;0.0001 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p&lt;0.0001 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>; Day 3 tone, p=0.0017 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0009 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>). (<bold>E</bold>) Cartoon figure of experiments for Morris water maze task (n = 12, 15, and 9 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>P633R/+</sup>, and <italic>Slc6a17</italic><sup>P633R/P633R</sup>, respectively). Detailed description in ‘Experimental procedures.’ (<bold>F</bold>) Latency to find the hidden platform during the training session. <italic>Slc6a17</italic><sup>P633R/P633R</sup> mice showed significantly different learning curve from <italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>P633R/+</sup> mice (two-way ANOVA; main effect of training day: F (4.381, 144.6) = 20.02, p&lt;0.0001; main effect of genotype: F (2, 33) = 22.65, p&lt;0.0001; main effect of training day × genotype: F (12, 198) = 2.389, p=0.0067; Tukey’s multiple-comparisons test: day 2, p=0.0150 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0078 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>; day 3, p=0.0403 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0388 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>; day 5, p=0.0023 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0243 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>; day 6, p=0.0199 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/+</sup>,p=0.0010 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0077 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>; day 7, p=0.0074 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0129 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>). (<bold>G</bold>) Representative swimming traces of each genotype. (<bold>H</bold>) Percentage of time spent in the target quadrant was significantly different (p=0.0031 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0325 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>). (<bold>I</bold>) Number of crossings through the platform area was significantly different (p=0.0003 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0123 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>). Data in the figure are presented as the mean ± SEM, with * indicating p&lt;0.05, ** indicating p&lt;0.01, *** indicating p&lt;0.001, and **** indicating p&lt;0.0001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig3">Figure 3D, H, and I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Generation of <italic>Slc6a17</italic> mutant mice.</title><p>(<bold>A</bold>) A schematic diagram illustrating the strategy for the generation of <italic>Slc6a17</italic>-KO mice by CRISPR/Cas9. Exon 2 encoding the first 99 amino acids of <italic>Slc6a17</italic> was deleted. (<bold>B</bold>) A schematic diagram illustrating the knock-in strategy of generating <italic>Slc6a17</italic><sup>P633R</sup> point mutation mice by CRISPR/Cas9. The mutated exon 12 was exchanged with endogenous exon 12, while both the HA- and the FLAG- tags were fused in-frame to the C terminus of the mutated <italic>Slc6a17</italic>. (<bold>C</bold>) Confocal images of the hippocampal CA3 region (left) and anterior thalamus (right) in both <italic>Slc6a17</italic><sup>HA/+</sup> and <italic>Slc6a17</italic><sup>P633R/+</sup> mice after immunocytochemistry with anti-Syp and anti-HA antibodies. Scale bar = 10 μm. (<bold>D</bold>) Sucrose gradient analysis of <italic>Slc6a17</italic><sup>P633R</sup>-HA LP2 fraction. SLC6A17<sup>P633R</sup> protein is indicated by HA and FLAG tags. HA and FLAG signals were mostly present in the LP2 input but not in layers 2–5 of the sucrose gradient, which were SV rich as shown by Syp and Syb2 positive immunoreactivities. On the other hand, SLC6A17<sup>G162R</sup> protein is still present in layers 2–5.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Original files of the full raw unedited blots for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Uncropped blots with the relevant bands lablled for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig3-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Phenotypical analysis of <italic>Slc6a17</italic><sup>P633R</sup> mice.</title><p>(<bold>A</bold>) <italic>Slc6a17</italic><sup>P633R</sup> mice were not significantly different the WT in body weight at the age of 10 wk, regardless of sex (male: n = 11, 7, and 10 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>P633R/+</sup>, and <italic>Slc6a17</italic><sup>P633R/P633R</sup>, respectively; p=0.7243 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.4078 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>; female: n = 11, 19, and 12 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>P633R/+</sup>, <italic>Slc6a17</italic><sup>P633R/P633R</sup>, respectively; p=0.9698 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=9,982 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>). (<bold>B</bold>) Locomotor activities of <italic>Slc6a17</italic><sup>P633R</sup> mice were not significantly different from the WT (n = 23, 28, and 17 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>P633R/+</sup>, <italic>Slc6a17</italic><sup>P633R/P633R</sup>, respectively; p&gt;0.9999 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.7803 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>). (<bold>C</bold>) NOR was not significantly different among <italic>Slc6a17</italic><sup>P633R</sup> mutant and WT mice (n = 23, 28, and 17 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>P633R/+</sup>, <italic>Slc6a17</italic><sup>P633R/P633R</sup>, respectively; p=0.4728 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.5776 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>). (<bold>D–F</bold>) <italic>Slc6a17</italic><sup>P633R</sup> homozygous mutants had lower level of anxiety in elevated plus maze (n = 22, 26, and 17 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>P633R/+</sup>, <italic>Slc6a17</italic><sup>P633R/P633R</sup>, respectively): overall locomotion was not significantly different (D, p=0.9974 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p&gt;0.9999 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); percentage of time spend in open arms was significantly increased in homozygous <italic>Slc6a17</italic><sup>P633R</sup> mutants (<bold>E</bold>, p=0.0002 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0035 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); travel distance in open arms was significantly increased in homozygous <italic>Slc6a17</italic><sup>P633R</sup> mutants (<bold>F</bold>, p=0.0016 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0044 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>).</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig3-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig3-figsupp2-v1.tif"/></fig></fig-group><p>We then investigated learning and memory in <italic>Slc6a17</italic><sup>P633R</sup> mice. In contextual and cued fear conditioning (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), <italic>Slc6a17</italic><sup>P633R/P633R</sup> mutants showed significantly less freezing behavior compared to <italic>Slc6a17</italic><sup>+/+</sup> and heterozygous (<italic>Slc6a17</italic><sup>P633R/+</sup>) mice on day 2 in Context-a environment (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). On day 3, <italic>Slc6a17</italic><sup>P633R/P633R</sup> mutants showed a lower level of freezing behavior induced by cued tone compared to <italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>P633R/+</sup> mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These results indicate that <italic>Slc6a17</italic><sup>P633R</sup> mice are defective in contextual and cued fear memory.</p><p>We then tested <italic>Slc6a17</italic><sup>P633R</sup> mice in the Morris water maze for hippocampal spatial learning and memory (<xref ref-type="fig" rid="fig3">Figure 3E</xref>; <xref ref-type="bibr" rid="bib76">Morris, 1984</xref>; <xref ref-type="bibr" rid="bib75">Morris et al., 1982</xref>). During training, <italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>P633R/+</sup> mice had a similar pattern in their learning curves with gradual decreases in the latency to find the platform in two sessions (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Similar to the <italic>Slc6a17</italic>-KO mice, <italic>Slc6a17</italic><sup>P633R/P633R</sup> mutants required significantly longer time to find the platform in both visible and hidden sessions (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Representative swimming traces of each genotype in probe trials are shown in <xref ref-type="fig" rid="fig3">Figure 3G</xref>. During the probe trial, <italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>P633R/+</sup> mice spent more time in the target quadrant (<xref ref-type="fig" rid="fig3">Figure 3H</xref>) and had more crossings through the platform area than <italic>Slc6a17</italic><sup>P633R/P633R</sup> mutants (<xref ref-type="fig" rid="fig3">Figure 3I</xref>).</p><p>Taken together, these data indicate that <italic>Slc6a17</italic><sup>P633R</sup> mice are also significantly impaired both in contextual and cued fear memory and in hippocampus-dependent long-term spatial learning. Because all the phenotypes of <italic>Slc6a17</italic><sup>P633R</sup> are similar to Slc6a7-KO, the point mutation P633R is a LOF mutation.</p></sec><sec id="s2-4"><title>Vesicular localization of SLC6A17</title><p>Previous studies with anti-SLC6A17 antibodies provided evidence that SLC6A17 was localized in SVs (<xref ref-type="bibr" rid="bib32">Fischer et al., 1999</xref>; <xref ref-type="bibr" rid="bib50">Kachidian et al., 1999</xref>; <xref ref-type="bibr" rid="bib72">Masson et al., 1999</xref>). We have now used multiple approaches to analyze the subcellular localization of SLC6A17.</p><p><italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> mice were generated with the C terminus of the endogenous SLC6A17 protein fused in frame with three repeats of the HA epitope (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). We used differential centrifugation to purify SVs from the brains of <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> mice (<xref ref-type="bibr" rid="bib30">Evans, 2015</xref>; <xref ref-type="bibr" rid="bib45">Huttner et al., 1983</xref>). As shown in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>, SLC6A17-HA was enriched in LP2 fraction, similar to the other SV proteins such as synaptotagmin 1 (Syt1) (<xref ref-type="bibr" rid="bib33">Geppert et al., 1994</xref>), vesicular ATPase (V-ATPase) (<xref ref-type="bibr" rid="bib22">Cidon and Sihra, 1989</xref>), and synaptobrevin 2 (Syb2) (<xref ref-type="bibr" rid="bib60">Link et al., 1992</xref>; <xref ref-type="bibr" rid="bib95">Schiavo et al., 1992</xref>), but different from postsynaptic proteins such as postsynaptic density 95 (PSD95) (<xref ref-type="bibr" rid="bib21">Cho et al., 1992</xref>; <xref ref-type="bibr" rid="bib109">Woods and Bryant, 1991</xref>). Sucrose gradient centrifugation of the LP2 fraction showed copurification of SLC6A17-HA with SV proteins including synaptophysin (Syp) (<xref ref-type="bibr" rid="bib48">Jahn et al., 1985</xref>; <xref ref-type="bibr" rid="bib59">Leube et al., 1987</xref>; <xref ref-type="bibr" rid="bib108">Wiedenmann and Franke, 1985</xref>), Syt1, and VGluT1 (<xref ref-type="bibr" rid="bib4">Bellocchio et al., 2000</xref>; <xref ref-type="bibr" rid="bib100">Takamori et al., 2000</xref>), but not with proteins localized to the postsynaptic membrane (PSD95) or (SNAP23) (<xref ref-type="bibr" rid="bib89">Ravichandran et al., 1996</xref>; <xref ref-type="bibr" rid="bib99">Suh et al., 2010</xref>), the endoplasmic reticulum (ER) (ERp72), the endosome (EEA1) (<xref ref-type="bibr" rid="bib77">Mu et al., 1995</xref>), and the proteosome (PSMC6) or the trans-Golgi network (synaptaxin 6, STX6) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Biochemical and genetically assisted electron microscopy (EM) validation of the vesicular localization of SLC6A17.</title><p>(<bold>A</bold>) A schematic diagram illustrating the knock-in strategy for generating <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> mice. More details in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>. (<bold>B</bold>) Higher magnification views of co-immunostaining by anti-Syp and anti-HA antibodies in the hippocampus. Scale bar = 10 μm. (<bold>C</bold>) Immunoisolation of SLC6A17-HA containing vesicles by the anti-HA antibody coated on magnetic beads. SLC6A17-HA fraction was positive for Syp, Syt1, Syb2, v-ATPase, VGluT1, VGluT2, and vGAT, but negative for GluT4 and transferrin receptor. (<bold>D</bold>) Further purification of the LP2 fraction by sucrose gradient showed that SLC6A17-HA was co-immunoisolated with Syp, Syt1, and VGluT1, but not PSD95, ERp72, EEA1, SNAP23, PSMC6, or STX6. (<bold>E</bold>) A schematic diagram illustrating the APEX2-based labeling strategy with AAV-PHP.eb virus mediated SLC6A17-APEX2 overexpression in vivo. SLC6A17 was fused in-frame to three repeats of the HA tag, a V5 tag, and APEX2. (<bold>F</bold>) Representative EM image of synaptic vesicles (SVs) labeled by SLC6A17-APEX2 and darkness distribution of DAB-positive and DAB-negative SVs in sections of <italic>Slc6a17</italic>-APEX2 mouse brains. Red arrow pointing to APEX2 labeled SVs. White arrow pointing to unlabeled SVs.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original files of the full raw unedited blots for <xref ref-type="fig" rid="fig4">Figure 4C and D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Uncropped blots with the relevant bands labeled for <xref ref-type="fig" rid="fig4">Figure 4C and D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Immunoisolation and immunohistochemistry of <italic>Slc6a17</italic>-HA mice.</title><p>(<bold>A</bold>) A schematic diagram illustrating the knock-in strategy for generating <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> KI mice. (<bold>B</bold>) Confocal images of the hippocampal region in <italic>Slc6a17</italic><sup>HA/+</sup> mice after immunocytochemistry with anti-Syp and anti-HA antibodies. Scale bar = 50 μm. (<bold>C</bold>) With fractions of whole brains by differential centrifugation, SLC6A17-HA was co-immunoisolated with synaptic markers including Syp, Syt1, Syb2, and V-ATPase, but not with PSD95. (<bold>D</bold>) Analysis of synaptic vesicles (SVs) isolated by anti-HA beads from <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> mice and from WT mice. 23 markers for organelles were analyzed to confirm SV specificity, and absence of markers of lysosome, Golgi, mitochondria, ER, endosome, proteasome, and postsynaptic cytoplasmic membrane. Scale bar = 10 μm.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Original files of the full raw unedited blots for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C and D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Uncropped blots with the relevant bands labeled for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C and D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Electron microscopy (EM) confirmation of the synaptic vesicle (SV) localization of SLC6A17-APEX2.</title><p>(<bold>A, C, E, G</bold>) Different views of SLC6A17-APEX2 overexpression. (<bold>B, D, F, H</bold>) Normal distribution of SV electron density in the corresponding images on the left.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig4-figsupp2-v1.tif"/></fig></fig-group><p>We used the anti-HA magnetic beads to immunoisolate SLC6A17-HA protein from <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> mice (<italic>Slc6a17</italic><sup>HA/+</sup>), with WT (<italic>Slc6a17</italic><sup>+/+</sup>) mice as a control (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). After examining markers of subcellular organelles, the fraction containing SLC6A17-HA was found to be co-localized with SV markers such as Syp, Syt1, Syb2, VATPase, and vesicular neurotransmitter transporters including VGluT1, VGluT2, and VGAT (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>), but not with markers of axons or dendrites (GLUT4 or transferrin receptor), ER (ERp72), the lysosome (LAMP2, LC3b, or cathepsin D), the cytoplasmic membrane (SNAP23, PSD95, and GluN1), the Golgi apparatus (GM130 and Goglin-97), mitochondria (VADC), the active zone (ERC1b/2), the endosome (EEA1), and the proteosome (PSMC6) (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). In addition, immunostaining of HA-tagged SLC6A17 in <italic>Slc6a17</italic><sup>HA/+</sup> mouse showed puncta co-localized with the anti-Syp positive immunoreactivity (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and B</xref>).</p><p>We also used genetically assisted EM to confirm SLC6A17 localization. APEX2 is derived from ascorbate peroxidase (APEX) and can be used to genetically label proteins for EM inspection (<xref ref-type="bibr" rid="bib57">Lam et al., 2015</xref>; <xref ref-type="bibr" rid="bib69">Martell et al., 2017</xref>). We fused APEX2 in-frame to the C terminus of SLC6A17 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). SLC6A17-APEX2 fusion protein was delivered into the adult mouse brain via systemic administration of a BBB-crossing adeno-associated virus (AAV9) variant AAV-PHP.eb, under human synapsin promoter (hSyn) (<xref ref-type="bibr" rid="bib17">Chan et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Deverman et al., 2016</xref>; <xref ref-type="fig" rid="fig4">Figure 4E</xref>). SLC6A17-APEX2 was indeed localized on the SVs (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A, C, E, and G</xref>). Quantitative analysis showed distinct populations of SVs distinguished by electron density (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B, D, F, and H</xref>).</p><p>Our results from biochemistry and genetically assisted EM analysis support the SV localization of SLC6A17.</p></sec><sec id="s2-5"><title>Functional significance of the SV localization of SLC6A17</title><p>We used a monoclonal anti-Syp antibody to immunoisolate SVs from brains of <italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>-/-</sup> mice (<xref ref-type="bibr" rid="bib10">Boyken et al., 2013</xref>; <xref ref-type="bibr" rid="bib36">Grønborg et al., 2010</xref>; <xref ref-type="bibr" rid="bib48">Jahn et al., 1985</xref>). Quantitative proteomic analysis showed that only SLC6A17 was dramatically reduced in SVs immunopurified from <italic>Slc6a17</italic>-KO mice, whereas other transporters such as VGluT1, VGluT2, VGluT3, VGAT, VMAT2, SV2A, SV2B, SV2C, ZnT3, and VAT-1 were not different between <italic>Slc6a17</italic><sup>-/-</sup> and <italic>Slc6a17</italic><sup>+/+</sup> (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Thus, <italic>Slc6a17</italic> gene knockout indeed specifically decreased SLC6A17 on SVs, but none of the other transporters.</p><p>To investigate the functional significance of the subcellular localization of SLC6A17, we examined the subcellular localization of SLC6A17<sup>P633R</sup> protein in the mouse brain. SLC6A17<sup>P633R</sup> mutation was found in human ID patients (<xref ref-type="bibr" rid="bib47">Iqbal et al., 2015</xref>) and transfection of a cDNA encoding this mutant into cultured primary neurons from mice found that its distribution was changed from that of the WT SLC6A17 (<xref ref-type="bibr" rid="bib47">Iqbal et al., 2015</xref>), but the disturbance on SV localization was unambiguous and the effect of the mutation on the endogenous protein was unknown.</p><p>With the endogenous SLC6A17<sup>P633R</sup> protein tagged by the HA and FLAG epitopes (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), we found that SLC6A17<sup>P633R</sup>-HA signal was primarily localized to the soma with no overlap detected with the anti-Syp antibody staining (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). We also performed differential centrifugation and sucrose gradient purification. HA and FLAG signals were presented in LP2 but did not co-purified with SVs in sucrose gradients, indicated that the SLC6A17<sup>P633R</sup> protein was not present in SVs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>).</p></sec><sec id="s2-6"><title>Presence of Gln in immunoisolated SVs</title><p>Neurotransmitters such as Glu and GABA have been reliably found in SVs immunoisolated from the mammalian brain (<xref ref-type="bibr" rid="bib11">Bradberry et al., 2022</xref>; <xref ref-type="bibr" rid="bib16">Burger et al., 1991</xref>; <xref ref-type="bibr" rid="bib15">Burger et al., 1989</xref>; <xref ref-type="bibr" rid="bib18">Chantranupong et al., 2020</xref>; <xref ref-type="bibr" rid="bib70">Martineau et al., 2013</xref>). Previous experiments suggest that SLC6A17 could transport Ala, Gly, Leu, and Pro into PC12 and CHO cells (<xref ref-type="bibr" rid="bib80">Parra et al., 2008</xref>), or Ala, Gly, Leu, Pro, Cys, Gln, Gly, His, and Ser into HEK cells (<xref ref-type="bibr" rid="bib111">Zaia and Reimer, 2009</xref>). However, none of the reported substrates of SLC6A17 has been reliably detected in SVs.</p><p>To analyze the contents of SVs, we used the anti-Syp antibody to immunoisolate SVs from the mouse brain (<xref ref-type="bibr" rid="bib16">Burger et al., 1991</xref>; <xref ref-type="bibr" rid="bib15">Burger et al., 1989</xref>; <xref ref-type="bibr" rid="bib70">Martineau et al., 2013</xref>), before their contents were subjected to chemical analysis by LC-MS (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). IgG was used as a control for the anti-Syp antibody in SV immunoisolation. The specificity of the anti-Syp antibody-mediated SVs immunoisolation was confirmed (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>), with a total of 16 markers for SVs, lysosomes, endosomes, the Golgi apparatus, mitochodria, the ER, and pre- or postsynaptic membrane.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Presence of glutamine in synaptic vesicles (SVs) from the mouse brain.</title><p>(<bold>A</bold>) A schematic diagram illustrating the procedure to immunoisolate SVs with the anti-Syp antibody for liquid chromatography coupled to mass spectrometry (LC-MS) analysis of the contents in the SVs. (<bold>B</bold>) Representative MS results showing Gln signals from SVs immunoisolated by the anti-Syp antibody (anti-Syp) vs. the control sample immunoisolated with IgG. (<bold>C</bold>) Volcano plot of chemical contents in the SVs isolated by anti-Syp vs. IgG. The y axis shows p-values in log<sub>10</sub> and the x axis shows the log<sub>2</sub> of the ratio of the level of a molecule immunoisolated by anti-Syp vs. IgG. Classical neurotransmitters Glu, GABA, and ACh, as well as previously reported substrates of SLC6A17 are listed. (<bold>D</bold>) Ratios of the level of a chemical immunoisolated by anti-Syp vs. IgG (transformed into log<sub>2</sub>). (<bold>E–I</bold>) Chemicals were quantified to mole per μg antibody (n = 12 for each group from four different animals with three replicates each): Glu (<bold>E</bold>, p&lt;0.0001 for anti-Syp vs. IgG); GABA (<bold>F</bold>, p&lt;0.0001 for anti-Syp vs. IgG); ACh (<bold>G</bold>, p&lt;0.0001 for anti-Syp vs. IgG); Gln (<bold>H</bold>, p&lt;0.0001 for anti-Syp vs. IgG); Ser (<bold>I</bold>, p=0.7553 for anti-Syp vs. IgG).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig5">Figure 5C–I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Liquid chromatography coupled to mass spectrometry (LC-MS) analysis of SVs immunoisolated by the anti-Syp antibody.</title><p>(<bold>A</bold>) Analysis of SVs isolated by the anti-Syp antibody. 16 markers for organelles were analyzed to confirm the SV specificity, with no detection of markers for lysosome, Golgi, mitochondria, ER, endosome and postsynaptic cytoplasmic membrane. IgG was used as a control. (<bold>B–G</bold>) Neurotransmitter contents in SVs isolated by the anti-Syp antibody. Representative LC-MS signals of anti-Syp and IgG group are shown, each graph was normalized: Glu (<bold>B</bold>), GABA (<bold>D</bold>), and ACh (<bold>F</bold>) highly enriched; 5-HT (<bold>C</bold>), histamine (<bold>E</bold>), and dopamine (<bold>G</bold>) moderately enriched.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Original files of the full raw unedited blots for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>Uncropped blots with the relevant bands labeled for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig5-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig5-figsupp1-v1.tif"/></fig></fig-group><p>The ratio of a molecule immunoisolated with the anti-Syp antibody to that with IgG was calculated and analyzed (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>). Glu, GABA, and ACh were reliably detected from SVs immunoisolated with the anti-Syp antibody (<xref ref-type="fig" rid="fig5">Figure 5C–G</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B, D, and F</xref>). Monoamine neurotransmitters such as 5-hydroxytryptamine (5-HT) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>), dopamine (DA) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1G</xref>), and histamine (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>) could also be detected but not further analyzed for this paper. Hereafter, we focused our analysis on Glu, GABA, and ACh as the positive controls and the nine previously reported AAs as candidate substrates of SLC6A17 in vivo.</p><p>Surprisingly, of the nine AAs reported previously using cultured cells, eight (Ala, Gly, Leu, Pro, Cys, Gly, His, and Ser) were not found to be significantly enriched in SVs (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>). Only Gln was reproducibly found to be enriched in the anti-Syp antibody immunoisolated SVs (<xref ref-type="fig" rid="fig5">Figure 5C, D and H</xref>).</p><p>There could be several reasons why molecules transported into cultured cells were not detected in SVs of the mouse brain, including, for example, relative abundance in subsets of SVs specific for different transporters, or the redundancy of multiple transporters for a single molecule among the nine candidates. However, the positive finding of Gln in the SVs is definitive.</p></sec><sec id="s2-7"><title>Enrichment of Gln in SLC6A17 containing SVs from the mouse brain</title><p>The above results with SVs purified by the anti-Syp antibody revealed Gln presence in SVs, but did not show association of Gln with specific transporter on SV, because Syp is a universal marker of SVs (<xref ref-type="bibr" rid="bib48">Jahn et al., 1985</xref>; <xref ref-type="bibr" rid="bib108">Wiedenmann and Franke, 1985</xref>; <xref ref-type="bibr" rid="bib59">Leube et al., 1987</xref>; <xref ref-type="bibr" rid="bib98">Südhof et al., 1987</xref>). To determine the potential relationship of SLC6A17 with Gln in the SVs, we used magnetic beads coated with the anti-HA antibody to immunoisolate SLC6A17-positive SVs from <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> mice (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>).</p><p>The anti-HA beads could enrich SVs containing SLC6A17 from the brains of <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> mice but not from wt mice, as confirmed by the analysis of 23 markers (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). SVs thus isolated (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) were subject to chemical analysis with LC-MS (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). Glu, GABA, and ACh were detected in SVs containing SLC6A17-HA (<xref ref-type="fig" rid="fig6">Figure 6C–G</xref>), consistent with the immunoblot results that these SVs contained VGluT1, VGluT2, and VGAT (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Significant enrichment of Gln was detected in SVs containing SLC6A17-HA (<xref ref-type="fig" rid="fig6">Figure 6C, D, and H</xref>). By contrast, the other eight AAs had not been found to be enriched in SVs containing SLC6A17-HA (<xref ref-type="fig" rid="fig6">Figure 6C, D, and I</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Glutamine (Gln) enrichment in synaptic vesicles (SVs) containing SLC6A17.</title><p>(<bold>A</bold>) A schematic diagram illustrating the procedure to isolate SLC6A17-containing SVs for chemical analysis of SV contents. (<bold>B</bold>) Representative result showing MS Gln signals in SVs immunoisolated by the anti-HA beads in <italic>Slc6a17</italic><sup>HA/+</sup> mice vs. those from <italic>Slc6a17</italic><sup>+/+</sup> mice. (<bold>C</bold>) Volcano plot of chemical contents in the SVs immunoisolated by anti-HA beads from <italic>Slc6a17</italic><sup>HA/+</sup> mice vs. <italic>Slc6a17</italic><sup>+/+</sup> mice. The y axis shows p-values in log<sub>10</sub> and the x axis shows the log<sub>2</sub> of the ratio of the level of a molecule immunoisolated by anti-HA beads from <italic>Slc6a17</italic><sup>HA/+</sup> mice vs. that from <italic>Slc6a17</italic><sup>+/+</sup> mice. Classical neurotransmitters such as Glu, GABA, and ACh as well as the previously reported substrates of SLC6A17 are listed. (<bold>D</bold>) Ratios of the level of a chemical immunoisolated by anti-HA beads from <italic>Slc6a17</italic><sup>HA/+</sup> mice vs. that from <italic>Slc6a17</italic><sup>+/+</sup> mice (transformed into log<sub>2</sub>). (<bold>E–I</bold>) Contents of SLC6A17-containing SVs were quantified to mole per 10 μl anti-HA beads (n = 12, for each group from four different animals with three replicates each): Glu (<bold>E</bold>, p&lt;0.0001 for <italic>Slc6a17</italic><sup>HA/+</sup> vs. <italic>Slc6a17</italic><sup>+/+</sup>); GABA (<bold>F</bold>, p&lt;0.0001 for <italic>Slc6a17</italic><sup>HA/+</sup> vs. <italic>Slc6a17</italic><sup>+/+</sup>); ACh (<bold>G</bold>, p&lt;0.0001 for <italic>Slc6a17</italic><sup>HA/+</sup> vs. <italic>Slc6a17</italic><sup>+/+</sup>); Gln (<bold>H</bold>, p&lt;0.0001 for <italic>Slc6a17</italic><sup>HA/+</sup> vs. <italic>Slc6a17</italic><sup>+/+</sup>); Ser (<bold>I</bold>, p=0.7553 for <italic>Slc6a17</italic><sup>HA/+</sup> vs. <italic>Slc6a17</italic><sup>+/+</sup>).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig6">Figure 6C–I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig6-v1.tif"/></fig><p>Thus, only Gln has been reproducibly found to be enriched in SLC6A17 containing SVs in vivo.</p></sec><sec id="s2-8"><title>Sufficiency of SLC6A17 for Gln localization in SVs</title><p>To further investigate whether SLC6A17 could increase Gln in SVs, we overexpressed SLC6A17 in the mouse brain. AAV-PHP.eb was systematic administrated to express SLC6A17-HA in the mouse brain (OE-SLC6A17-HA) under hSyn promoter (<xref ref-type="bibr" rid="bib17">Chan et al., 2017</xref>; <xref ref-type="bibr" rid="bib28">Deverman et al., 2016</xref>; <xref ref-type="fig" rid="fig7">Figure 7A</xref>). The overexpressed SLC6A17-HA protein was localized in SVs, as analyzed by immunoblot (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Increased glutamine (Gln) transport into synaptic vesicles (SVs) containing SLC6A17 but not into SVs containing SLC6A17<sup>G162R</sup>.</title><p>(<bold>A</bold>) A schematic diagram illustrating the strategy for the AAV-PHP.eb virus-mediated in vivo overexpression of SLC6A17-HA and SLC6A17<sup>G162R</sup>-HA. (<bold>B</bold>) Volcano plot of chemical contents in the SVs isolated by anti-HA beads from the OE-SLC6A17-HA mice vs. WT mice. The y axis shows p-values in log<sub>10</sub> and the x axis shows the log<sub>2</sub> of the ratio of the level of a molecule immunoisolated by anti-HA beads from mice overexpressing SLC6A17-HA vs. that from WT mice. Classical neurotransmitters and previously reported substrates of SLC6A17 are listed. (<bold>C–G</bold>) Contents of OE-SLC6A17-containing SV are quantified to mole per 10 μl HA beads (n = 10, for each group from three different animals with three replicates in two animal and four replicates in one animal): Glu (<bold>C</bold>, p&lt;0.0001 for OE-SLC6A17-HA vs. WT); GABA (<bold>D</bold>, p&lt;0.0001 for OE-SLC6A17-HA vs. WT); ACh (<bold>E</bold>, p&lt;0.0001 for OE-SLC6A17-HA vs. WT); Gln (<bold>F</bold>, p&lt;0.0001 for OE-SLC6A17-HA vs. WT); (<bold>G</bold>, p=0.1655 for OE-SLC6A17-HA vs. WT). (<bold>H</bold>) Volcano plot comparing the chemical contents of SVs containing OE-SLC6A17-HA with those containing OE-SLC6A17<sup>G162R</sup>-HA. Classical neurotransmitters and nine putative substrates of SLC6A17 are listed. Glu is the only classical transmitter significantly increased. Gln is the only substrates significantly increased in SLC6A17-HA containing SVs vs. SLC6A17<sup>G162R</sup>-HA containing SVs. (<bold>I</bold>) Volcano plot comparing the chemical contents of SVs containing OE-SLC6A17-HA with those containing OE-Syp-HA. Classical neurotransmitters and nine putative substrates of SLC6A17 are listed. Gln is the only substrates significantly increased in SLC6A17 containing SVs vs. Syp-HA containing SVs. (<bold>J–N</bold>) Contents of SVs containing SCL6A17-HA, SVs containing OE-SLC6A17<sup>G162R</sup>-HA, SVs containing Syp-HA immunosilated by anti-HA immunoisolation with that from WT mouse brains were quantified to mole per 10 μl HA beads and normalized to Syb2 relative abundance in WB (n = 9, 9, 6, and 6 for OE-SLC6A17-HA, OE-SLC6A17<sup>G162R</sup>-HA, OE-Syp-HA, and WT, respectively, from different animals with three replicates each): Glu (<bold>J</bold>, p&lt;0.0001 for OE-SLC6A17-HA vs. OE-SLC6A17<sup>G162R</sup>-HA; p&lt;0.0001 for OE-SLC6A17-HA vs. WT; p&lt;0.0001 for OE-SLC6A17<sup>G162R</sup>-HA vs. WT; p=0.0009 for OE-Syp-HA vs. WT; p=0.1551 for OE-SLC6A17-HA vs. OE-Syp-HA; p=0.0618 for OE-SLC6A17<sup>G162R</sup>-HA vs. OE-Syp-HA); GABA (<bold>K</bold>, p=0.0002 for OE-SLC6A17-HA vs. WT; p=0.0002 for OE-SLC6A17<sup>G162R</sup>-HA vs. WT; p=0.0039 for OE-Syp-HA vs. WT; p=0.9885 for OE-SLC6A17-HA vs. OE-SLC6A17<sup>G162R</sup>-HA; p=0.9000 for OE-SLC6A17-HA vs. OE-Syp-HA; p=0.5840 for OE-SLC6A17<sup>G162R</sup>-HA vs. OE-Syp-HA); ACh (<bold>L</bold>, p=0.0019 for OE-SLC6A17-HA vs. WT; p=0.0006 for OE-SLC6A17<sup>G162R</sup>-HA vs. WT; p=0.0467 for OE-Syp-HA vs. WT; p=0.1054 for OE-SLC6A17-HA vs. OE-SLC6A17<sup>G162R</sup>-HA; p=0.7563 for OE-SLC6A17-HA vs. OE-Syp-HA; p=0.8702 for OE-SLC6A17<sup>G162R</sup>-HA vs. OE-Syp-HA); Gln (<bold>M</bold>, p=0.001 for OE-SLC6A17-HA vs. OE-SLC6A17<sup>G162R</sup>-HA; p=0.0018 for OE-SLC6A17-HA vs. OE-Syp-HA; p=0.0003 for OE-SLC6A17-HA vs. WT; p&lt;0.0001 for OE-SLC6A17<sup>G162R</sup>-HA vs. WT; p=0.0189 for OE-Syp-HA vs. WT; p=0.2749 for OE-SLC6A17<sup>G162R</sup>-HA vs. OE-Syp-HA); Ser (<bold>N</bold>, p=0.626 for OE-SLC6A17-HA vs. OE-SLC6A17<sup>G162R</sup>-HA; p=0.8551 for OE-SLC6A17-HA vs. OE-Syp-HA; p=0.9874 for OE-SLC6A17-HA vs. OE-Syp-HA; p&lt;0.0865 for OE-SLC6A17<sup>G162R</sup>-HA vs. WT; p=0.1017 for OE-Syp-HA vs. WT).</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig7">Figure 7B–I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Virally mediated overexpression of SLC6A17-HA and SLC6A17<sup>G162R</sup>-HA.</title><p>(<bold>A</bold>) Analysis of synaptic vesicles (SVs) isolated by anti-HA beads from mice overexpressing OE-Syp-HA, OE-SLC6A17-HA, and OE-SLC6A17<sup>G162R</sup>-HA. High levels of association with SV markers (Syp and Syb2) were detected in both samples, indicating Syp-HA, SLC6A17-HA and SLC6A17<sup>G162R</sup> proteins were all localized on the SVs. Liquid chromatography coupled to mass spectrometry (LC-MS) results normalization was based on immunoblot analysis of SV markers. (<bold>B</bold>) Volcano plot of the contents from SVs purified by anti-HA immunoisolation from OE-SLC6A17<sup>G162R</sup>-HA overexpressing mice compared to that from WT mice. (<bold>C</bold>) Quantification of His levels (p&lt;0.0001 for OE-SLC6A17 vs. WT). (<bold>D</bold>) Quantification of His levels (p=0.2433 for OE-SLC6A17 vs. OE-SLC6A17<sup>G162R</sup>-HA; p=0.0018 for OE-SLC6A17 vs. Syp-HA; p=0.2735 for OE-SLC6A17 vs. WT; p=0.9993 for OE-SLC6A17<sup>G162R</sup>-HA vs. WT; p=0.9998 for Syp-HA vs. WT). (<bold>E</bold>) Sucrose gradient analysis of <italic>Slc6a17</italic><sup>G162R</sup>-HA LP2 fraction. <italic>Slc6a17</italic><sup>G162R</sup>-HA was associated with layers 2–4, which were rich with SV markers such as Syt1, Syp, Syb2, and VGlut1.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Original files of the full raw unedited blots for <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A and E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig7-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7s1sdata2"><label>Figure 7—figure supplement 1—source data 2.</label><caption><title>Uncropped blots with the relevant bands labeled for <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A and E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig7-figsupp1-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig7s1sdata3"><label>Figure 7—figure supplement 1—source data 3.</label><caption><title>Data points for <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig7-figsupp1-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig7-figsupp1-v1.tif"/></fig></fig-group><p>We then analyzed the chemical contents of immunoisolated SVs by LC-MS. The ratio of a molecule purified from OE-SLC6A17-HA mice vs. that purified from WT mice was calculated and analyzed (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). SVs from mice overexpressing SLC6A17-HA contained significantly higher levels of Glu and GABA (<xref ref-type="fig" rid="fig7">Figure 7B–G</xref>). Gln was dramatically increased (<xref ref-type="fig" rid="fig7">Figure 7B and F</xref>), to the extent that Gln was higher than GABA in SVs overexpressing SLC6A17-HA (<xref ref-type="fig" rid="fig7">Figure 7B, D, F, K, and M</xref>). Quantification of the enriched molecules in SVs containing SLC6A17-HA showed Gln to be approximately two times that of GABA (<xref ref-type="fig" rid="fig7">Figure 7D and F</xref>). In addition, His was moderately increased in SVs overexpressing SLC6A17-HA (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C, D</xref>). These results from our virally introduced overexpression experiments support that SLC6A17 is sufficient for Gln transport into SVs in vivo.</p></sec><sec id="s2-9"><title>Functional significance of SLC6A17 for Gln presence in the SVs</title><p><italic>SLC6A17</italic><sup>G162R</sup> is another pathogenic mutation of human ID (<xref ref-type="bibr" rid="bib47">Iqbal et al., 2015</xref>), with a point mutation in the third transmembrane domain of SLC6A17. To investigate whether SLC6A17<sup>G162R</sup> affected Gln transportation, we used AAV-PHP.eb to overexpress either SLC6A17<sup>G162R</sup>-HA or Syp-HA in mouse brains under hSyn promoter. Overexpressed SLC6A17<sup>G162R</sup>-HA was still localized on SVs (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>, E). Overexpressed Syp-HA was previously reported to be localized on SVs (<xref ref-type="bibr" rid="bib18">Chantranupong et al., 2020</xref>), which we confirmed (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>).</p><p>LC-MS analysis of contents of SVs immunoisolated by the anti-HA beads from OE-Syp-HA mice, when compared with immunoprecipitates from the brains of WT mice, would indicate SV enriched molecules. As expected, Glu, GABA, and ACh were all found to be enriched in these SVs (<xref ref-type="fig" rid="fig7">Figure 7J, K, and L</xref>), whereas Ser was not enriched (<xref ref-type="fig" rid="fig7">Figure 7N</xref>).</p><p>The contents of SVs immunoisolated from OE-SLC6A17<sup>G162R</sup>-HA mice, when compared with that from OE-Syp-HA and WT mice, would indicate molecules enriched in SVs containing SLC6A17<sup>G162R</sup> mutation, above the general contents of all SVs. Levels of Glu and GABA in SVs containing SLC6A17<sup>G162R</sup>-HA were higher than those in WT mice (<xref ref-type="fig" rid="fig7">Figure 7J and K</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>), but not significantly different with those from OE-Syp-HA mice (<xref ref-type="fig" rid="fig7">Figure 7J and K</xref>). These results indicate that the subset of SVs containing SLC6A17<sup>G162R</sup>-HA did not enrich Glu or GABA beyond the levels of Glu and GABA in the general population of SVs. The level of Gln in SVs containing SLC6A17<sup>G162R</sup>-HA were much lower than that in from OE-SLC6A17-HA mice (<xref ref-type="fig" rid="fig7">Figure 7M</xref>), indicating that SLC6A17<sup>G162R</sup> was defective in transporting Gln into SVs in vivo. The level of Gln in SVs containing SLC6A17<sup>G162R</sup>-HA was higher than that in WT mice, but not different from that in OE-Syp-HA mice (<xref ref-type="fig" rid="fig7">Figure 7M</xref>). These results indicate that Gln was present in SVs, but not enriched in SVs containing SLC6A17<sup>G162R</sup>-HA comparing to the general populations of SVs expressing Syp-HA. The levels of the other eight AAs in SVs containing SLC6A17<sup>G162R</sup>-HA were not significantly higher than those in WT mice (<xref ref-type="fig" rid="fig7">Figure 7N</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B and D</xref>).</p><p>We compared the contents of SVs immunoisolated from OE-SLC6A17-HA mice with those from either OE-Syp-HA mice or OE-SLC6A17<sup>G162R</sup>-HA mice. The levels of GABA and ACh were not different among SVs from mice expressing SLC6A17-HA, Syp-HA, or SLC6A17<sup>G162R</sup>-HA (<xref ref-type="fig" rid="fig7">Figure 7I, I, K, and L</xref>), indicating that SVs containing SLC6A17-HA were similar to the general populations of SVs. A moderate enrichment of Glu in SVs overexpressing SLC6A17-HA, compared to those overexpressing SLC6A17<sup>G162R</sup>-HA, was observed (<xref ref-type="fig" rid="fig7">Figure 7H and J</xref>). Gln was increased most dramatically in SVs overexpressing SLC6A17-HA, compared to those overexpressing Syp-HA (<xref ref-type="fig" rid="fig7">Figure 7I and M</xref>) or SLC6A17<sup>G162R</sup>-HA (<xref ref-type="fig" rid="fig7">Figure 7H and M</xref>). The levels of Ser (<xref ref-type="fig" rid="fig7">Figure 7N</xref>), Pro, Gly, Met, Leu, Ala, and Cys were not significantly increased in SVs overexpressing SLC6A17-HA, compared to those overexpressing Syp-HA (<xref ref-type="fig" rid="fig7">Figure 7I</xref>) or SLC6A17<sup>G162R</sup>-HA (<xref ref-type="fig" rid="fig7">Figure 7H</xref>).</p><p>Taken together, our data provide in vivo evidence that the pathogenic mutation <italic>SLC6A17</italic><sup>G162R</sup> could not transport Gln into SVs in the mouse brain, supporting the functional significance of Gln in the SVs.</p></sec><sec id="s2-10"><title>Requirement of SLC6A17 for Gln transport into the SV in <italic>Slc6a17</italic> knockout mice</title><p>We have found <italic>Slc6a17</italic>-KO mice to be defective in learning and memory (<xref ref-type="fig" rid="fig2">Figure 2B–H</xref>) and SLC6A17 protein was exclusively decreased on SVs. We then investigated Gln level in these mice. The anti-Syp antibody was used to immunoisolate SVs from the brains of <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>+/-</sup> and <italic>Slc6a17</italic><sup>-/-</sup> mice (<xref ref-type="fig" rid="fig8">Figure 8A–H</xref>).</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Reduced levels of glutamine (Gln) in the synaptic vesicles (SVs) of <italic>Slc6a17</italic> KO mice.</title><p>Contents of SVs purified by the anti-Syp antibody from <italic>Slc6a17</italic>-KO mice were quantified to mole per 10 μg antibody (n = 12 for <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>+/-</sup>, <italic>Slc6a17</italic><sup>-/-</sup>, from four different animals with three replicates each): Glu (<bold>A</bold>, p=0.2749 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.2466 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); GABA (<bold>B</bold>, p=0.665 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.2503 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); ACh (<bold>C</bold>, p=0.9993 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.7186 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); Pro (<bold>D</bold>, p=0.9986 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.8035 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); Leu (<bold>E</bold>, p=0.826 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.61 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); Gly (<bold>F</bold>, p=0.3211 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.442 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); Ala (<bold>G</bold>, p=0.9092 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.1321 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); Gln (<bold>H</bold>, p=0.002 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.0489 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); Cys (<bold>I</bold>, p=0.3753 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.5718 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); Met (<bold>J</bold>, p=0.9735 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.13 for +/- vs. <italic>Slc6a17</italic><sup>-/-</sup>); Ser (<bold>K</bold>, p=0.8678 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.7834 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>); His (<bold>L</bold>, p&gt;0.9999 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>, p=0.9922 for <italic>Slc6a17</italic><sup>+/-</sup> vs. <italic>Slc6a17</italic><sup>-/-</sup>).</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig8">Figure 8A–L</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig8-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig8-v1.tif"/></fig><p>LC-MS analysis of SVs revealed that Gln was the only molecule found to be decreased in SVs from <italic>Slc6a17</italic><sup>-/-</sup> mice, compared with <italic>Slc6a17</italic><sup>+/+</sup> or <italic>Slc6a17</italic><sup>+/-</sup> mice (<xref ref-type="fig" rid="fig8">Figure 8H</xref>). Quantitative analysis showed that the levels of classic transmitters such as Glu (<xref ref-type="fig" rid="fig8">Figure 8A</xref>), GABA (<xref ref-type="fig" rid="fig8">Figure 8B</xref>), and ACh (<xref ref-type="fig" rid="fig8">Figure 8C</xref>) were not significantly different among the SVs immunoisolated from the <italic>Slc6a17</italic><sup>+/+</sup>, the <italic>Slc6a17</italic><sup>+/-</sup>, or the <italic>Slc6a17</italic><sup>-/-</sup> mice. The levels of the other eight AAs were also not significantly different among SVs immunoisolated from all three genotypes (<xref ref-type="fig" rid="fig8">Figure 8D–F, G, I– L</xref>). These results further support that Gln was transported into the SVs by SLC6A17 in vivo.</p></sec><sec id="s2-11"><title>Physiological requirement of SLC6A17 for Gln presence in the SVs in adult mice</title><p>To investigate whether the endogenous SLC6A17 is required in adulthood for Gln presence in the SVs, we used a viral-mediated CRISPR-based approach to remove the <italic>Slc6a17</italic> gene from adult mice.</p><p>Briefly, <italic>Slc6a17</italic><sup>-HA-2AiCre</sup> mice were crossed with LSL-Cas9 transgene-carrying mice (<xref ref-type="bibr" rid="bib83">Platt et al., 2014</xref>) and injected with an AAV-PHP.eB to express Syp-HA and guide RNAs (gRNA) targeting <italic>Slc6a17</italic> (AAV-PHP.eb-hSyn-DIO-Syp-HA-U6-sgRNAs) (<xref ref-type="fig" rid="fig9">Figure 9A</xref>, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A</xref>). A tandemly arrayed tRNA-gRNA structure was used to maximize the cleavage possibility in vivo (<xref ref-type="bibr" rid="bib84">Port and Bullock, 2016</xref>; <xref ref-type="bibr" rid="bib110">Xie et al., 2015</xref>; <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A</xref>). This strategy caused the excision of the <italic>Slc6a17</italic> gene and simultaneous expression of Syp-HA to tag SVs specifically in <italic>Slc6a17</italic>-expressing cells of adult mice (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A</xref>). <italic>Slc6a17</italic>-HA was significantly reduced both in the homogenates of total brains and in immunoisolated SVs from AAV-sgRNA/<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> mice (<xref ref-type="fig" rid="fig9">Figure 9B</xref>, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1B</xref>).</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Physiological requirement of SLC6A17 for glutamine (Gln) transport into synaptic vesicles (SVs) in vivo.</title><p>(<bold>A</bold>) A schematic diagram illustrating the strategy of Cas9-mediated cleavage of <italic>Slc6a17</italic> specifically in <italic>Slc6a17</italic>-positive neurons, and simultaneous labeling of all SVs in these neurons by Syp-HA. (<bold>B</bold>) Immunoblot results showing SLC6A17 protein was significantly reduced in targeted neurons, while Syp-HA was efficiently tagged onto the SVs of these neurons. (<bold>C</bold>) Volcano plot of contents of SVs from AAV-sgRNA/<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> targeted neurons compared to contents of SVs from control (AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup>) neurons. Glu, GABA, ACh, and the nine previously reported substrates of SLC6A17 are listed. (<bold>D</bold>) Ratios of the level of a molecule from the SVs of AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> neurons vs. the level of the same molecule from SVs of AAV-sgRNA/<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup> neurons shown as fold change (log<sub>2</sub> transformed). GABA level was significantly increased (p=0.0034 for AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> vs. AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup>). Gln level was significantly decreased (p&lt;0.0001 for AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> vs. AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup>). (<bold>E–H</bold>) Contents of SVs from <italic>Slc6a17</italic> containing neurons were quantified to mole per 10 μl HA beads (n = 18, 27 for <italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup> and <italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup>, respectively, from six and nine different animals with three replicates each): Glu (<bold>E</bold>, p=0.0005 for AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> vs. AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup>); GABA (<bold>F</bold>, p=0.0032 for AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> vs. AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup>); Gln (<bold>G</bold>, p&lt;0.0001 for AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> vs. AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup>); Ser (<bold>H</bold>, p=0.0979 for AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> vs. AAV-sgRNA /<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup>).</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig9">Figure 9C-I</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig9-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig9sdata2"><label>Figure 9—source data 2.</label><caption><title>Original files of the full raw unedited blots for <xref ref-type="fig" rid="fig9">Figure 9B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig9-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig9sdata3"><label>Figure 9—source data 3.</label><caption><title>Uncropped blots with the relevant bands labeled for <xref ref-type="fig" rid="fig9">Figure 9B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig9-data3-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig9-v1.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>CRISPR/Cas9-mediated <italic>Slc6a17</italic> gene cleavage in <italic>Slc6a17</italic> expressing cells of adult mice.</title><p>(<bold>A</bold>) A schematic diagram illustrating the strategy for Cas9-mediated cleavage of <italic>Slc6a17</italic> specifically in <italic>Slc6a17</italic>-positive neurons, and simultaneous labeling of SVs by Syp-HA. A single tRNA-gRNA allowed multiple gRNAs being efficiently produced, which could be precisely excised in vivo by the endogenous RNases, to improve editing efficiency of Cas9 system. (<bold>B</bold>) SLC6A17 protein in <italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup> mice were efficiently removed. The protein level of SLC6A17 was measured in the input supernatant used for immunoisolation.</p><p><supplementary-material id="fig9s1sdata1"><label>Figure 9—figure supplement 1—source data 1.</label><caption><title>Original files of the full raw unedited blots for <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig9-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig9s1sdata2"><label>Figure 9—figure supplement 1—source data 2.</label><caption><title>Uncropped blots with the relevant bands labeled for <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86972-fig9-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig9-figsupp1-v1.tif"/></fig></fig-group><p>Importantly, when the SV contents from the brains of knockout (AAV-sgRNA/<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>+</sup>) and control (AAV-sgRNA/<italic>Slc6a17</italic><sup>iCre</sup>/Cas9<sup>-</sup>) mice were compared after LC-MS analysis, Gln was the only vesicular content significantly decreased in SVs from the knockout mice (<xref ref-type="fig" rid="fig9">Figure 9C, D, and H</xref>).</p><p>To our surprise, GABA and Glu were moderately increased (<xref ref-type="fig" rid="fig9">Figure 9C–F</xref>). The level of ACh, and those of the other eight AAs (Ala, Gly, Leu, Pro, Cys, Gly, His, and Ser), was not significantly changed in the SVs from adult <italic>Slc6a17</italic> knockout mice (<xref ref-type="fig" rid="fig9">Figure 9C, D, G, and I</xref>). The increased levels of Glu and GABA in SVs of virally mediated KO mice were different from the absence of Glu and GABA increases in the straightforward <italic>Slc6a17</italic> KO (<xref ref-type="fig" rid="fig8">Figure 8A and B</xref>), making the significance of the observed increases of Glu and GABA in the virally mediated <italic>Slc6a17</italic> knockout unclear.</p><p>These results indicate that SLC6A17 is physiologically necessary for Gln in SVs, but not for the other eight AAs.</p></sec><sec id="s2-12"><title>Functional significance of Gln in SVs supported by analysis of mice carrying a mutation mimicking a human ID mutation</title><p>To further address the question whether Gln transport into the SVs was functionally important, we examined the SVs from <italic>Slc6a17</italic><sup>P633R</sup> mutant mice (<xref ref-type="fig" rid="fig10">Figure 10A–L</xref>). This mutation mimicked one of the human ID mutations (<xref ref-type="bibr" rid="bib47">Iqbal et al., 2015</xref>), and its behavioral phenotypes have been found by us (<xref ref-type="fig" rid="fig3">Figure 3</xref>). We have shown that the SLC6A17<sup>P633R</sup> protein was not localized in the SVs (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>).</p><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Reduced levels of glutamine (Gln) in the synaptic vesicles (SVs) of <italic>Slc6a17</italic><sup>P633R</sup> mice.</title><p>Contents of SVs purified by the anti-Syp antibody from <italic>Slc6a17</italic><sup>P633R</sup> mice were quantified to mole per 10 μg antibody (n = 12 for all genotype, from four different animals with three replicates each): Glu (<bold>A</bold>, p=0.9804 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.9982 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); GABA (<bold>B</bold>, p=0.4432 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup> p=0.3898 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); ACh (<bold>C</bold>, p=0.8175 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.9804 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); Pro (<bold>D</bold>, p=0.9674 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.9989 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); Leu (<bold>E</bold>, p=0.7116 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.6696 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); Gly (<bold>F</bold>, p=0.7376 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.9971 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); Ala (<bold>G</bold>, p=0.9871 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.986 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); Gln (<bold>H</bold>, p=0.0029 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.0117 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); Cys (<bold>I</bold>, p=0.8143 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.5475 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); Met (<bold>J</bold>, p=0.9942 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.995 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); Ser (<bold>K</bold>, p=0.9955 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.8355 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>); His (<bold>L</bold>, p=0.6177 for <italic>Slc6a17</italic><sup>+/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>, p=0.4316 for <italic>Slc6a17</italic><sup>P633R/+</sup> vs. <italic>Slc6a17</italic><sup>P633R/P633R</sup>).</p><p><supplementary-material id="fig10sdata1"><label>Figure 10—source data 1.</label><caption><title>Data points for <xref ref-type="fig" rid="fig10">Figure 10A–L</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86972-fig10-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-fig10-v1.tif"/></fig><p>LC-MS analysis of contents from SVs showed a significant decrease in Gln level in <italic>Slc6a17</italic><sup>P633R/P633R</sup>, compared to <italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>P633R/+</sup> mice (<xref ref-type="fig" rid="fig10">Figure 10H</xref>). The difference in Gln between <italic>Slc6a17</italic><sup>+/+</sup> and <italic>Slc6a17</italic><sup>P633R/+</sup> was not statistically significant (<xref ref-type="fig" rid="fig10">Figure 10H</xref>). The levels of Glu (<xref ref-type="fig" rid="fig10">Figure 10A</xref>), GABA (<xref ref-type="fig" rid="fig10">Figure 10B</xref>), and ACh (<xref ref-type="fig" rid="fig10">Figure 10C</xref>) in SVs were not significantly different among <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>P633R/+</sup>, and <italic>Slc6a17</italic><sup>P633R/P633R</sup> mice. The levels of the other eight AAs in the SVs were also not significantly different among <italic>Slc6a17</italic><sup>+/+</sup>, <italic>Slc6a17</italic><sup>P633R/+</sup>, and <italic>Slc6a17</italic><sup>P633R/P633R</sup> mice (<xref ref-type="fig" rid="fig10">Figure 10D–G, I–L</xref>).</p><p>Thus, mislocalization of SLC6A17<sup>P633R</sup> outside the SVs correlates with the inability of Gln enrichment in SVs (<xref ref-type="fig" rid="fig10">Figure 10H</xref>), as well as behavioral impairment (<xref ref-type="fig" rid="fig3">Figure 3D, F, H, and I</xref>), establishing the significance of SLC6A17 localization on the SVs.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We have taken multiple approaches to analyze seven kinds of genetically modified mice (four modified in the germline and one in adult brains) and our results indicating that Gln as an endogenous substrate of SLC6A17 and SLC6A17 is necessary and sufficient for Gln presence in SVs in vivo.</p><p>We have discovered the presence of Gln in the SVs and shown that it is functionally important because two mutations pathogenic for human ID patients both resulted in reduction of Gln in the SVs. We discuss these findings in basic neurobiology with implications in human ID pathology.</p><sec id="s3-1"><title>The discovery of Gln in SVs and its functional significance</title><p>With behavioral studies in two types of <italic>Slc6a17</italic> mutant mice, we have shown that one ID pathogenic <italic>Slc6a17</italic> mutation (<italic>Slc6a17</italic><sup>P633R</sup>) causes defective learning and memory (<xref ref-type="fig" rid="fig3">Figure 3</xref>), similar to the phenotype of <italic>Slc6a17</italic> knockout mice (<xref ref-type="fig" rid="fig2">Figure 2</xref>). With biochemical purifications and genetically assisted EM, we have confirmed SLC6A17 localization on SVs (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>We demonstrate the functional significance of the SV localization of SLC6A17 by showing that the human ID mutation <italic>Slc6a17</italic><sup>P633R</sup> causes mislocalization of SLC6A17 outside the SVs (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). Gln transport into the SVs was decreased in <italic>Slc6a17</italic><sup>P633R</sup> mutant mice (<xref ref-type="fig" rid="fig10">Figure 10I</xref>).</p><p>With multiple rounds of biochemical purification of SVs and chemical analysis of SV contents of genetically modified mice, we have found that Gln is present in SVs containing SLC6A17 and that SLC6A17 is sufficient for Gln presence in SVs (<xref ref-type="fig" rid="fig5">Figures 5</xref>—<xref ref-type="fig" rid="fig7">7</xref>). With two lines of germline mutant mice and virally mediated gene edited mice, we demonstrate that Gln is the only molecule reliably and reproducibly reduced in SVs when <italic>Slc6a17</italic> gene is deleted (<xref ref-type="fig" rid="fig8">Figures 8</xref> and <xref ref-type="fig" rid="fig9">9</xref>).</p><p>We have also characterized mice carrying a human ID mutation SLC6A17<sup>G162R</sup> and found it could not transport Gln into SVs (<xref ref-type="fig" rid="fig7">Figure 7</xref>), further supporting the importance of Gln in SVs. Thus, two mutations pathogenic in human ID are both LOF mutations: SLC6A17<sup>P633R</sup> with mislocalization outside the SVs and the SLC6A17<sup>G162R</sup> with defective Gln transport into the SVs.</p><p>The fact that all four kinds of <italic>SLC6A17</italic> LOF mutations (two KOs, two point mutations) have led to reduction in Gln in SVs strongly support the functional significance of Gln in SVs.</p></sec><sec id="s3-2"><title>Functional mechanisms of Gln in SVs</title><p>There are three possible functions for Gln in SVs: serving as a neurotransmitter, serving as a carbon source, and serving in a function so far unknown.</p><p>The first possibility is the most attractive. SLC6A17 is a member of the SLC6 family, which is also known as the NTT family because many members of this family are transporters for neurotransmitters (<xref ref-type="bibr" rid="bib8">Blakely and Edwards, 2012</xref>; <xref ref-type="bibr" rid="bib14">Bröer, 2006</xref>; <xref ref-type="bibr" rid="bib56">Kristensen et al., 2011</xref>; <xref ref-type="bibr" rid="bib93">Rudnick et al., 2014</xref>): SLC6A1 for GABA (<xref ref-type="bibr" rid="bib38">Guastella et al., 1992</xref>; <xref ref-type="bibr" rid="bib23">Clark et al., 1992</xref>; <xref ref-type="bibr" rid="bib9">Borden et al., 1994</xref>; <xref ref-type="bibr" rid="bib63">Lopez-Corcuera et al., 1992</xref>), SLC6A2 for noradrenaline (<xref ref-type="bibr" rid="bib79">Pacholczyk et al., 1991</xref>), SLC6A3 for DA (<xref ref-type="bibr" rid="bib35">Giros et al., 1991</xref>; <xref ref-type="bibr" rid="bib53">Kilty et al., 1991</xref>; <xref ref-type="bibr" rid="bib96">Shimada et al., 1991</xref>), SLC6A4 for 5-HT or serotonin (<xref ref-type="bibr" rid="bib7">Blakely et al., 1991</xref>; <xref ref-type="bibr" rid="bib43">Hoffman et al., 1991</xref>), and SLC6A5 and SLC6A9 for Gly (<xref ref-type="bibr" rid="bib38">Guastella et al., 1992</xref>; <xref ref-type="bibr" rid="bib97">Smith et al., 1992</xref>; <xref ref-type="bibr" rid="bib61">Liu et al., 1993</xref>). Most of these are cytoplasmic transporters for transporting neurotransmitters from the synaptic cleft into the presynaptic cytoplasm.</p><p>The presence of the SLC6A17 protein on the vesicular membrane further supports the possibility that it is a neurotransmitter transporter because most of the vesicular transporters with known substrates transport neurotransmitters. If this is true for SLC6A17, then Gln would be a good candidate for a new neurotransmitter. However, this exciting possibility remains to be investigated. For Gln to be a transmitter, in addition to its presence in the SVs, more criteria should be satisfied: (1) it should be released from the nerve terminals upon electric stimulation, (2) it should be active on postsynaptic membrane, (3) it should be up-taken by a cytoplasmic transporter back into the presynaptic terminal or be removed otherwise (such as degraded enzymatically), and (4) a pharmacological blocker inhibiting its activity should interfere with chemical transmission in a physiologically significant context. Because Gln is abundant both intracellularly and extracellularly, we expect that demonstration of all the above would take some time, and likely by many laboratories.</p><p>There is a Glu/Gln cycle in which Glu released from neurons is taken up by glia and transformed into Gln, followed by Gln release from glia and taken up by neurons and transformed into Glu (<xref ref-type="bibr" rid="bib3">Bak et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Benjamin and Quastel, 1972</xref>; <xref ref-type="bibr" rid="bib78">Ottersen et al., 1992</xref>; <xref ref-type="bibr" rid="bib102">van den Berg and Garfinkel, 1971</xref>). Gln uptake across the neuronal cytoplasmic membrane relies on system A transporters (<xref ref-type="bibr" rid="bib67">Mackenzie et al., 2003</xref>; <xref ref-type="bibr" rid="bib90">Reimer et al., 2000</xref>; <xref ref-type="bibr" rid="bib103">Varoqui et al., 2000</xref>; <xref ref-type="bibr" rid="bib106">Weiss et al., 2003</xref>), while Gln uptake across the glia cytoplasmic membrane uses system L (<xref ref-type="bibr" rid="bib26">Deitmer et al., 2003</xref>; <xref ref-type="bibr" rid="bib51">Kanai et al., 1998</xref>), system N transporters (<xref ref-type="bibr" rid="bib13">Bröer and Brookes, 2001</xref>; <xref ref-type="bibr" rid="bib20">Chaudhry et al., 2002</xref>; <xref ref-type="bibr" rid="bib19">Chaudhry et al., 1999</xref>), and system ASC (<xref ref-type="bibr" rid="bib12">Bröer et al., 2000</xref>). It is unlikely that SLC6A17 and the Gln transports could be part of the Glu/Gln cycle because (1) the Glu/Gln cycle uses cytoplasmic transporters for Gln, not vesicular transporters for Gln; (2) Gln is transformed into Glu in the cytoplasm of neurons before being transported in the SVs as Glu; and (3) in all of our experiments presented here, when <italic>SLC6A17</italic> was genetically disrupted, Gln was consistently decreased, but Glu was either unchanged but not concomitantly increased, which was against the expectation of the Glu/Gln cycle. The only result in which Glu was increased when SLC6A17 was decreased came from an experiment with virally mediated genetic knockdown of SLC6A17 (<xref ref-type="fig" rid="fig9">Figure 9E</xref>), but GABA was also increased in that experiment (<xref ref-type="fig" rid="fig9">Figure 9F</xref>). When the same experiment was carried with a germline genetic knockout of <italic>SLC6A17</italic>, Glu was not changed when SLC6A17 was decreased (<xref ref-type="fig" rid="fig9">Figure 9A</xref>).</p><p>The possibility of Gln as a carbon source is based on the fact that it is one of the major carbon sources (<xref ref-type="bibr" rid="bib41">Hensley et al., 2013</xref>; <xref ref-type="bibr" rid="bib91">Reitzer et al., 1979</xref>). It would be very curious if a carbon source should be stored in the SVs. It would suggest an entirely new function for Gln in the nerve terminal that has never been suspected before and may require considerable efforts before one can fully understand.</p></sec><sec id="s3-3"><title>Other substrates for SLC6A17</title><p>Of the nine AAs (Ala, Gly, Leu, Pro, Cys, Gln, Gly, His, and Ser) previously reported to be in vitro substrates for SLC6A17 transport in cell lines (<xref ref-type="bibr" rid="bib80">Parra et al., 2008</xref>; <xref ref-type="bibr" rid="bib111">Zaia and Reimer, 2009</xref>), we have reliably and reproducibly found evidence supporting only one (Gln) as present in vivo in all five types of experiments conducted with SV purifications: SVs immunoisolated from the WT brains by anti-Syp (<xref ref-type="fig" rid="fig5">Figure 5</xref>), SVs immunoisolated from the brains of mice with the HA tag fused in frame to the endogenous SLC6A17 protein (<xref ref-type="fig" rid="fig6">Figure 6</xref>), SVs immunoisolated from mice with virally introduced overexpression of Syp-HA, SVs immunoisolated from mice with virally introduced overexpression of SLC6A17<sup>G162R</sup>-HA, and SVs immunoisolated from mice with virally introduced overexpression of SLC6A17-HA (<xref ref-type="fig" rid="fig7">Figure 7</xref>). While we did observe a moderate increase of His in one set of experiments (OE SLC6A17-HA vs. WT), we did not find evidence for its changes in other experiments.</p><p>Because multiple transporters can transport AAs, and the relative contribution of each transporter varies and the relative abundance of each small molecules and their detectability varies, we cannot rule out the possibility that SLC6A17 can contribute to the transport of other AAs into the SVs. However, our results can establish that Gln is transported in vivo.</p><p>In summary, integration of genetics, biochemistry, behavioral analysis, mass spectrometry, and electron microscopy has resulted in the discovery of Gln as a novel chemical in SVs, provided in vivo evidence that SLC6A17 is necessary and sufficient for Gln in SVs, generated animal models for, and suggested pathogenetic mechanism of, human ID. However, while we have answered the question how <italic>Slc6a17</italic> mutations may cause ID in animals, our research has also raised more questions. This natural process of questions begetting answers begetting questions is intrinsic to scientific inquiries and is a source of endless fun in conducting research.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Reagents</title><p>Chemical reagents for biochemical purification and immunoisolation were all ordered form Sigma-Aldrich. The following antibodies were purchased from Synaptic Systemmouse anti-Synaptophysin 1 (Cat# 101011 for IP), rabbit anti-Synaptophysin 1 (Cat# 101002 for IB), rabbit anti-Synaptotagmin 1 (Cat# 105008 for IB), rabbit anti-VGLUT 1 (Cat# 135302 for IB), rabbit anti-VGAT (Cat# 131002 for IB), rabbit anti-VGLUT 2 (Cat# 135402 for IB), rabbit anti-Proton ATPase (Cat# 109002 for IB), rabbit anti-Synaptobrevin 2 (Cat# 104202 for IB), rabbit anti-SV2A (Cat# 119002 for IB), rabbit anti-SNAP23 (Cat# 111002 for IB), mouse anti-GluN1(Cat# 114011 for IB), and rabbit anti-ERC 1b/2 (Cat# 143003 for IB). The following antibodies were purchased from Abcam: mouse anti-Synaptophysin (Cat# ab52636 for IF), mouse Alexa Fluor 488 anti-Synaptophysin (Cat# ab196379 for IF), rabbit Anti-M6PR rabbit (Cat# ab124767 for IB), anti-Cathepsin D (Cat# ab75852 for IB), mouse anti-PSMC6 (Cat# ab22639 for IB), rabbit anti-GLUT4 (Cat# ab33780 for IB), and rabbit anti-Transferring receptor (Cat# ab84036 for IB). The following antibodies were purchased from Cell Signaling Technology: rabbit anti-LAMP2 (Cat# 49067 for IB), rabbit anti-EEA1 (Cat# 3288 for IB), rabbit anti-ERp72 (Cat# 5033 for IB), rabbit anti-Goglin-97 (Cat# 1292S for IB), rabbit anti-GM130 (Cat# 12480 for IB), rabbit anti-VDAC (Cat# 4661S for IB), rabbit anti-Syntaxin 6 (Cat# 2869 for IB), rabbit anti-LC3B (Cat# 2775 for IB), and rabbit anti-HA (Cat# 3724S for IF or IB). Mouse anti-PSD95 (Cat# 75028 for IB) were purchase from NeuroMab. Mouse anti-FLAG M2 HRP conjugated antibodies (Cat# A8592 for IB) were purchase from Sigma.</p></sec><sec id="s4-2"><title>Animals</title><p>All animal procedures were approved by the Animal Center of Peking University, and the experiments were carried out in accordance with the guidelines of Institutional Animal Care and Use Committee (IACUC) of Peking University. Mice were weaned at the age of 21 d. Mice were maintained under standard conditions (12 hr light, 12 hr dark schedule). Room temperature was 23 ± 1°C. Humidity was 40–60%. Mice for behavior assays were 10–16 weeks old.</p><p>All transgenic mouse lines were generated in C57BL/6J background. Ai14 mice were a gift from Dr. Hongkui Zeng. Rosa26-LSL-Cas9 mice were obtained from The Jackson Laboratory (028551). <italic>Slc6a17</italic><sup>-2A-CreERT2</sup> and <italic>Slc6a17</italic>-KO mice were generated by CasGene biotech (Beijing, China). <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> and <italic>Slc6a17</italic><sup>P633R</sup> mice were generated by Biocytogen (Beijing, China). Mutant strains were generated by CRISPR/Cas9. Approximately 1.5 kb homologous arms upstream and downstream of target site were cloned into the targeting vector. The cleavage efficiency of single-guide RNAs (sgRNAs) targeting <italic>SLC6A17</italic> were tested in HEK cells. The sgRNAs selected for final injection were 5′-<named-content content-type="sequence">ccaacggacgctatggaagcggc-3′</named-content> for <italic>Slc6a17</italic><sup>-2A-CreERT2</sup> mice; 5′-<named-content content-type="sequence">catgcccaggtaacacctatggg-3</named-content>′ and 5′-<named-content content-type="sequence">cctgttaacaacactatctgaca-3</named-content>′ for <italic>Slc6a17</italic>-KO mice; 5′-<named-content content-type="sequence">actgaggggtgctggccaagagg-3</named-content>′ for <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> mice; and 5′-<named-content content-type="sequence">ctgctagaatccaggaggcagg-3</named-content>′ for <italic>Slc6a17</italic><sup>P633R</sup> mice. All mutant strain were confirmed by PCR sequencing of the targeting regions. Southern blots were performed by Biocytogen for <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> and <italic>Slc6a17</italic><sup>P633R</sup> mice to rule out random insertions. For CreERT2 induction, tamoxifen was administrated intraperitoneally (i.p<italic>.</italic>) 1 mg/day/mice for five consecutive days at the age of 4–5 wk. Two weeks after tamoxifen injection, mice were killed for histology examination.</p></sec><sec id="s4-3"><title>Histology and immunocytochemistry</title><p>Mice were anesthetized, perfused, and post-fixed as described previously (<xref ref-type="bibr" rid="bib62">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib86">Qin and Luo, 2009</xref>). Briefly, mice were deeply anesthetized with tribromoethanol (250 mg/kg; i.p.) and transcardially perfused with cold 0.1 M PBS followed by 4% paraformaldehyde (PFA) in 0.1 M PBS. Brains were fixed overnight in 4% PFA at 4°C and then immersed in 30% sucrose until it sank to the bottom at 4°C. It was embedded in the Tissue-Tek O.C.T. compound and frozen in a freezing microtome chamber (Leica CM 3050; Leica). Sections were 40 μm thick and collected on adhesion glass slides (P/N.80312–3161, CITOTEST). <italic>Slc6a17</italic><sup>2A-CreERT2</sup>::Ai14 mice sections were washed with 0.3% Trtion X-100 in PBS (PBST) and then placed under cover-slips with a mounting solution (Fluoroshield with DAPI, F6057, Sigma). Sections were imaged by confocal microscope (Zesis LSM710) or Slide scanner (Zeiss Axio Scan. Z1). For immunofluorescence, freshly prepared slides were washed with PBST, followed by 1 hr 10% normal goat serum (in PBST) to block nonspecific binding. Primary antibodies were diluted to working concentrations in PBST and incubated with slides overnight at 4°C. Slides were washed with PBST and incubated with secondary antibodies for 1 hr at room temperature. After PBST washes, slides were placed under cover-slips with a mounting solution. For double staining in <xref ref-type="fig" rid="fig3">Figure 3B</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>, anti-HA antibody (RmAb, 1:200 dilution) was applied and labeled in Alexa Fluor 546, then Alexa Fluor 488 Anti-Syp (RmAb, ab196379, Abcam, 1:200 dilution) was applied. Slides were placed under cover-slips with a mounting solution and images were analyzed by confocal microscope (Zesis LSM710).</p></sec><sec id="s4-4"><title>Behavioral tests</title><p>Mice were placed in the experiment room for at least 1 hr before behavioral tests. All experiments were performed with the genotypes blind to the researchers. 70% ethanol was used to clear odor cues after each test.</p><sec id="s4-4-1"><title>Open Field tests</title><p>Experiments were conducted in a square Plexiglas apparatus (40 × 40 × 35 cm) with illumination kept at 100–200 lux. Mice were gently placed in the center of the apparatus and allowed to explore for 30 min. Activities were recorded by a digital camera (HDR-XR550, SONY) set directly above the apparatus. After each trial, the apparatus was cleaned and the animals put back to home cage. Videos were analyzed by a home-made program created for <italic>Slc6a17</italic>-KO mice and Open Field (Mobile Datum, Shanghai, China) for <italic>Slc6a17</italic><sup>P633R</sup> mice. The home-made program is based on OpenCV. Briefly, mice were extracted by subtracting background, which was updated for each frame in order to prevent environmental light shift. The center of the mouse was calculated, from which the distance was determined.</p></sec><sec id="s4-4-2"><title>Novel object recognition task</title><p>The experimental protocol was adopted from a previous report (<xref ref-type="bibr" rid="bib6">Bevins and Besheer, 2006</xref>). On the first day, mice were individually habituated in an open box (40 × 40 × 25 cm). Next day, two identical objects (O) were placed into left and right corners of the box and mice were allowed to explore for 10 min. Object recognition was tested 1 hr later. One familiar object (O) was replaced by a novel object (N) before mice were placed back into the box. Mice were allowed to explore freely for 5 min. The time spent in the exploring the object was measured. Discrimination ratio was calculated by novel object interaction time/total interaction time with both objects. Testing sessions were recorded by a digital camera (HDR-XR550, Sony) and analyzed by software (Mobile Datum).</p></sec><sec id="s4-4-3"><title>Morris water maze</title><p>The Morris water maze task was modified according to previously described procedures (<xref ref-type="bibr" rid="bib42">Hitti and Siegelbaum, 2014</xref>; <xref ref-type="bibr" rid="bib87">Qin et al., 2017</xref>). The maze contained a round pool (diameter: 120 cm) and a round platform (diameter: 10 cm, 2 cm below the water surface). Water was 50 cm deep and set at 20 ± 1°C. Visual cues were placed above the pool. Titanium white was added into water to make it opaque for mice. We trained mice for four 1 min trials per day. If a mouse successfully found the platform, it was taken back to home cage 15 s after locating the platform. If a mouse failed to find the platform during 1 min, it was gently placed on platform for 15 s then taken back to the home cage. On days 1 and 2, cued learning was conducted to find the platform marked with a visible object. Mice were trained from different start points at each trial. On days 3–7, the object was removed while mice were trained with different start points to locate the hidden platform whose location was different with cue learning session. The latency for each animal to find the platform was recorded. On day 8, spatial memory was tested with a 1 min probe trial in which the platform was removed. Crossings into the platform area and total time spent in the target platform quadrant were recorded. The trajectories of probe trial were analyzed by Noldus Video Tracking Software (Ethovision XT 15, Noldus, Netherlands).</p></sec><sec id="s4-4-4"><title>Fear conditioning</title><p>A 3-day delay fear-conditioning protocol was employed to test fear memory (<xref ref-type="bibr" rid="bib42">Hitti and Siegelbaum, 2014</xref>; <xref ref-type="bibr" rid="bib87">Qin et al., 2017</xref>). A conditioning chamber (25 cm × 25 cm × 40 cm) with two types of contexts (context a: black walls, metal net floor for electrical stimulation; context b: white walls and white plastic floor) was used. On day 1, mice were trained in context a. Two rounds of training were performed. Each round consisted of a 1 min adaptation of environment, followed by a cued tone (30 s, 300 Hz, 90 dB sound) and a foot shock (2 s, 0.75 mA constant current). On day 2, contextual fear memory was assayed by placing the mice back in context a for 300 s. On day 3, mice were placed in context a. After 180 s, a training tone was sounded for 180 s. 5% acetic acid were used to clean chambers between day 3 and day 2. Two kinds of apparatus were used. <italic>Slc6a17</italic>-KO mice were tested in Fear Conditioning (Mobile Datum) and <italic>Slc6a17</italic><sup>P633R</sup> mice were tested in Startle and Fear Combined System (Panlab, Spain). Animal activities were recorded and the percentage of time spent freezing (defined as the absence of all movement except for respiration) was measured by the software accordingly. Fear Conditioning (Mobile Datum) is a video-based recording system, so freezing time was reanalyzed by a double-blinded researcher to revise software variations. Startle and Fear Combined System (Panlab) is a gravity-based recording system.</p></sec><sec id="s4-4-5"><title>Elevated plus maze</title><p>The experimental protocol was adopted from previous reports (<xref ref-type="bibr" rid="bib55">Kouser et al., 2013</xref>; <xref ref-type="bibr" rid="bib85">Powell et al., 2004</xref>). Mice were placed in the center of a white plastic elevated plus maze, each arm was 33 cm long and 5 cm wide, with 15-cm-high opaque plastic walls on closed arms. Mice were allowed to explore for 5 min under the white light (~20 lux). Animal activities were recorded and analyzed by a software (Mobile Datum).</p></sec></sec><sec id="s4-5"><title>Subcellular fractionation</title><p>Experimental protocols were based on previously described methods for SV purification (<xref ref-type="bibr" rid="bib30">Evans, 2015</xref>; <xref ref-type="bibr" rid="bib45">Huttner et al., 1983</xref>). Homogenate buffer (0.32 M sucrose and 5 mM HEPES-NaOH, pH 7.4, protease inhibitor cocktail [Complete EDTA-free, Roche]) was pre-cooled on ice, and all operations were conducted on ice. Whole mouse brains were homogenized (kept as fraction H) in the homogenate buffer in a Potter Elvehjem homogenizer (Wheaton Instruments, USA, 9 strokes at 900 rpm) and centrifuged at 1000 × <italic>g</italic> for 10 min. The supernatant was kept as Fraction S1 and pellet containing large membranes was resuspended (kept as Fraction P1). Fraction S1 was then centrifuged at 13,000 × <italic>g</italic> for 20 min to yield a crude synaptosomal pellet (kept as Fraction P2), and remaining supernatant collected as Fraction S2. Synaptosomes in Fraction P2 were osmotic-lysed by adding 9 volumes of ice-cold ddH<sub>2</sub>O (protease inhibitor cocktail added), followed by quick homogenization (3 strokes, 2000 rpm) and 1/20 volume 1 M HEPES-NaOH (pH 7.4) was added. The osmotic-lysed samples were incubated on ice for 40 min to maximize yields. Lysates were then centrifuged at 25,000 × <italic>g</italic> for 20 min. Supernatant was collected as Fraction LS1 and pellet containing synaptic plasma membranes was resuspended (kept as Fraction LP1). Fraction LP2 was obtained after centrifugation of fraction LS1 for 2 hr at 165,000 × <italic>g</italic> in a SW40 Ti rotor (Beckman, USA). Corresponding supernatant was collected as Fraction LS2. Further purification of the SVs in Fraction LP2 was performed by centrifugation on a continuous sucrose gradient. Fraction LP2 was resuspended in gradient buffer (40 mM sucrose, 5 mM HEPES-NaOH, pH 7.4) and 200 μl (1 mg/ml) resuspended fraction LP2 was layered onto a 11 ml 50–800 mM continuous sucrose gradient. The gradient was centrifuged at 65,000 × <italic>g</italic> for 5 hr in SW40 Ti rotor and then divided to 11 equal fractions from the top to the bottom. 4 volumes of pre-cooled methanol (–20°C) was added into sub-fractions to precipitate proteins. Proteins were collected by centrifugation in 20,000 × <italic>g</italic> for 20 min. All centrifugations were conducted at 4°C.</p></sec><sec id="s4-6"><title>Immunoisolation of SVs</title><p>Experimental protocols were adopted from previous established methods (<xref ref-type="bibr" rid="bib16">Burger et al., 1991</xref>; <xref ref-type="bibr" rid="bib15">Burger et al., 1989</xref>; <xref ref-type="bibr" rid="bib70">Martineau et al., 2013</xref>). The entire experiments were conducted at 2–8°C. Whole brains were homogenized immediately after decapitation by ice-cold immunoisolation buffer (4 mM HEPES-KOH, 100 mM K<sub>2</sub>-tartrate, 2 mM MgCl<sub>2</sub>, pH 7.4, and protease inhibitor cocktail) in Potter Elvehjem homogenizer (15 strokes, 2000 rpm). Homogenates were centrifuged 35,000 × g for 25 min at 4°C. The supernatant (protein concentration 3 mg/ml) was used as input to incubated with magnetic beads coupled with antibody. For anti-Syp immunoisolation, anti-Syp (101 011, SySy) antibody was pre-incubated with Pierce protein G magnetic beads (88848, Thermo Scientific) in 0.1% BSA PBS at 4°C overnight. The anti-Syp antibody and mice IgG (02-6502, Invitrogen) were bound to Pierce protein G magnetic beads at the ratio of 33 μg of IgG per mg beads. For anti-HA immunoisolation, Pierce anti-HA magnetic beads (88837, Thermo Scientific) were used and washed just before each experiment. Beads were incubated with input supernatant for 2 hr with constant rotation at 4°C. Beads were washed six times by immunoisolation buffer after incubation. Following the final wash, beads were magnetically separated and vesicular contents were extracted by 50 μl 80%/20% methanol/H<sub>2</sub>O (–80°C) with 5 μM internal standards. To maximize the extraction efficiency and protein precipitation rate, the extraction mix was transferred to –20°C for 1 hr. The extraction mix was then centrifuged for 20 min at 20,000 × <italic>g</italic>, and supernatant was transferred to new vials subjected to LC-MS. The remaining beads were extracted by SDS loading buffer for immunoblot analysis.</p></sec><sec id="s4-7"><title>Immunoblotting</title><p>Proteins were extracted from each sample with SDS loading buffer (3% SDS, 15% glycerol, 180 mM Tris-HCl, 4% β-mercaptoethanol). For subcellular fractionation samples, protein concentrations were determined by the BCA protein assay (Pierce, 23250, Thermo Scientific), and equal quantities of proteins were subjected to SDS-PAGE. For immunoisolation samples, equal volumes of SDS loading buffer were added to magnetic isolated beads. Samples were incubated in 75°C for 20 min to better immunoblot transmembrane proteins. Briefly, samples were loaded to 10% SDS-PAGE gels (TGX FastCast Acrylamide Kits, 1610183, Bio-Rad) and transferred to 0.45 mm NC membranes (HATF00010, Millipore) for 2 hr. Membranes were subjected to 5% milk in TBST buffer (Tri-buffered Saline with Tween 20) at room temperature for 1 hr to block non-specific binding. Primary antibodies were prepared in TBST and incubated with membranes at 4°C overnight. Secondary antibodies were either anti-rabbit IgG HRP (A6154, Sigma, 1:5000 dilution) or anti-mouse IgG HRP (715-035-150, Jackson ImmunoResearch, 1:5000 dilution). Final results were visualized using chemiluminescence (Merck Millipore) in e-BLOT Touch Imager (e-BLOT Life Science, Shanghai).</p></sec><sec id="s4-8"><title>AAV plasmid construction and virus injection</title><p>AAV-PHP.eb viruses were packaged in HEK293T cells by the vector center of CIBR. The titers of AAVs were determined by real-time PCR. Viruses were subpackaged and stored in –80°C before use. All AAV constructs used for viral packaging were linearized by restriction enzymes to insert target sequences. Bacterial cultures were grown at 33°C. AAV-PHP.eb viruses were packaged by Vector Center in CIBR. Viruses were delivered retro-orbitally into the venous sinus of 6-week-old mice. For APEX2 staining, 2 * 10<sup>11</sup> particles of virus were injected. For gene overexpression and sgRNA expression, 1 * 10<sup>11</sup> particles of virus were injected. All plasmids will provided upon request. Sequence information is provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p></sec><sec id="s4-9"><title>Construction of pAAV-hSyn-SLC6A17-APEX2-WPRE-pA plasmid</title><p>This plasmid consisted of human <italic>SLC6A17</italic> cDNA, 3×HA tag, V5 tag, and APEX2. <italic>SLC6A17</italic> cDNA was cloned from commercially available cDNA library (Vigene, Shandong, China). The 3×HA tag (YPYDVPDYAGYPYDVPDYAGSYPYDVPDYA) were chosen the same version as <italic>Slc6a17</italic><sup>-HA-2A-iCre</sup> mice was in-frame fused with cDNA by GS4 linker (GGGGSGGGGS GGGGSGGGGS). V5-APEX2 sequence were cloned from mito-V5-APEX2 plasmid (#72480, Addgene). V5-APRX2 were first cloned into pAAV-hSyn-WPRE-pA plasmid. Then <italic>SLC6A17</italic>-HA was inserted before V5-APEX2. NEBuilder HiFi DNA Assembly Cloning Kit (NEB, E5520S) were used to insert fragments to backbone plasmids.</p></sec><sec id="s4-10"><title>Construction of pAAV-hSyn-SLC6A17-HA-WPRE-pA plasmid and pAAV-hSyn-SLC6A17<sup>G162R</sup>-HA-WPRE-pA plasmid</title><p><italic>SLC6A17</italic>-HA sequence consists of pAAV-hSyn-SLC6A17-APEX2. G162R point mutation was introduced by PCR (forward primer: 5′-<named-content content-type="sequence">attataatgtgatcatcAggtggagcatcttc-3</named-content>′; reverse primer: 5′-<named-content content-type="sequence">Tgatgatcacattataatacagcccc-3</named-content>′) in a middle plasmid without ITR element. Then the <italic>SLC6A17</italic><sup>G163R</sup>-HA sequence was cloned into pAAV-hSyn-WPRE-pA plasmid.</p></sec><sec id="s4-11"><title>Construction of pAAV-hSyn-DIO-Syp-HA-WPRE-pA-U6-3-t::gRNA WPRE-pA plasmid</title><p>tRNA-sgRNA design was modified from <xref ref-type="bibr" rid="bib84">Port and Bullock, 2016</xref>; <xref ref-type="bibr" rid="bib110">Xie et al., 2015</xref>. sgRNAs were chosen based on published database (<xref ref-type="bibr" rid="bib74">Michlits et al., 2020</xref>). The sequence of selected gRNA: sgRNA1 (5′- <named-content content-type="sequence">CGATGCTCCAGGCCACAAGGAGG</named-content>-3′, targeting exon 5); sgRNA2 (5′-<named-content content-type="sequence">GCCGTGGCAGCATTGGTGTGTGG</named-content>-3′, targeting exon 3); sgRNA3 (5′-<named-content content-type="sequence">TGGGCCTGGGCAACATCTGGAGG</named-content>-3′, targeting exon 2). Syp-HA sequence was synthesized and cloned into AAV backbone with hSyn promoter and DIO cassette.</p></sec><sec id="s4-12"><title>Electron microscopy with APEX2</title><p>Procedures for APEX2 based EM labeling were modified from previous reports (<xref ref-type="bibr" rid="bib57">Lam et al., 2015</xref>; <xref ref-type="bibr" rid="bib69">Martell et al., 2017</xref>). Briefly, the AAV-injected animals were anesthetized and perfused with PBS and 4% PFA and 1% glutaraldehyde (GA) for pre-fixation. Mouse brains were dissected and cut into approximately 1 mm<sup>3</sup> blocks and was added into 2.5% GA for post-fixation for 2 hr. Samples were then washed with 0.1 M phosphate buffer (PB). Following pre-incubation in 0.5 mg/ml 3,3-diaminobenzidine (DAB, D5905, Sigma) for 30 min, 0.03% H<sub>2</sub>O<sub>2</sub> (final concentration) was added into samples for APEX2 oxidation (note that different sources of DAB had considerable disparity, and D5905 produced the best signal than other DABs in our lab), although the recommended D8001 was poorer than D5905 (<xref ref-type="bibr" rid="bib64">Ludwig, 2020</xref>; <xref ref-type="bibr" rid="bib69">Martell et al., 2017</xref>). The reaction was monitored by the dark brown color in tissue block and was stopped by removing the DAB solution and washed three times with 0.1 M PB. Most of the successful DAB staining usually turned deep color within 10 min. After DAB staining, samples were incubated in 4% osmium tetroxide in 0.1 M PB on ice for 1 hr in dark environment. Samples were washed with ddH<sub>2</sub>O and incubated in 1% aqueous uranyl acetate overnight at 4°C. Next day, samples were dehydrated in graded ethanol series (30%, 50%, 75%, 85%, 95%, and 100%) at 4°C and rinsed once in acetone with each rinse for 10 min at room temperature. Samples were infiltrated in Epon 812 resin using a 1:3, 1:1, and 3:1 ratio of resin and acetone for 2 hr each followed by three infiltrations with 100% resin for 30 min each. Finally, samples were embedded in fresh resin in a vacuum oven for 24 hr at 65°C. Blocks were sectioned by UC7 ultramicrotome (Leica Microsystems, Vienna, Austria) into 70 nm. A 120 kV JEOL JEM-1400Flash TEM (JEOL, Japan) was used to image the brain and images were acquired by an XAROSA camera (Emsis GmbH, Muenster, Germany). Images were saved in a .tif format and were further analyzed using FIJI-ImageJ 2.1.0/1.53c (Wayne Rasband, NIH). The segmentation of SVs was performed using the TrakEM2 v1.0a (Univ/ETH Zurich) plugin in FIJI and the mean intensity of DAB+ or SV was quantified using a custom-made macro. Figures were created using OriginPro 2022.</p></sec><sec id="s4-13"><title>LC-MS for chemical detection</title><p>LC-MS was used to detect and quantify the chemical contents of samples based on previous reports (<xref ref-type="bibr" rid="bib1">Abu-Remaileh et al., 2017</xref>; <xref ref-type="bibr" rid="bib24">Contrepois et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Mackay et al., 2015</xref>; <xref ref-type="bibr" rid="bib107">Wernisch and Pennathur, 2016</xref>; <xref ref-type="bibr" rid="bib113">Zhang et al., 2014</xref>; <xref ref-type="bibr" rid="bib112">Zhang et al., 2012</xref>). A Vanquish UHPLC system coupled to a Q Exactive HF-X mass spectrometer (both instrument Thermo Fisher Scientific, USA) were used for LC-MS analysis along with SeQuant ZIC-HILIC column (150 mm × 2.1 mm, 3.5 μm, Merck Millipore, 150442) in the positive mode and SeQuant ZIC-pHILIC column (150 mm × 2.1 mm, 5 μm, Merck Millipore, 150460) in the negative mode. For ZIC-HILIC column, the mobile phase A was 0.1% formic acid in water and the mobile phase B was 0.1% formic acid in acetonitrile. The linear gradient was as following: 0 min, 80% B; 6 min, 50% B; 13 min, 50% B; 14 min, 20% B; 18 min, 20% B; 18.5 min, 80% B; 30 min, 80% B. The flow rate used was 300 μl/min and the column temperature was maintained at 30°C. For ZIC-pHILIC column, the mobile phase A is 20 mM ammonium carbonate in water, adjusted to pH 9.0 with 0.1% ammonium hydroxide solution (25%) and the mobile phase B is 100% acetonitrile. The linear gradient was as follows: 0 min, 80% B; 2 min, 80% B; 19 min, 20% B; 20 min, 80% B; 30 min, 80% B. The flow rate used is 150 μl/min and the column temperature is 25°C. Samples were maintained at 4°C in Vanquish autosampler. 3 µl of extracted metabolites were injected for each run. IP samples were subjected to ZIC-HILIC column in positive mode for major metabolites detection, and then subject to ZIC-pHILIC column in negative mode for orthogonal detection.</p><p>Calibration was performed prior to analysis using the Pierce Positive and Negative Ion Calibration Solutions (Thermo Fisher Scientific) every 7 d. Acetonitrile was LC-MS grade (A955, Thermo Fisher Scientific), and all other regents were LC-MS Optima grade from sigma. Isotope-labeled amino acids (sigma) as internal extraction standards were supplemented into extraction solution. Orbitrap mass spectrometer was operated with the following parameters: scanning in Full MS mode (2 μscans) from 70 to 1050 m/z at 70,000 resolution, with 4 kV spray voltage (3.5 kV for negative mode), 50 shealth gas (35 for negative mode), 12 auxiliary gas (8 for negative mode), capillary temperature 300°C, S-lens RF level 55, AGC target 1E6, and maximum injection time 200 ms.</p></sec><sec id="s4-14"><title>TMT-labeled SV proteomics</title><p>Procedures for quantitative SV proteomics were modified from previous reports (<xref ref-type="bibr" rid="bib10">Boyken et al., 2013</xref>; <xref ref-type="bibr" rid="bib36">Grønborg et al., 2010</xref>). Proteins were labeled using TMT10plex Isobaric Label Reagent Set (90113, Thermo Scientific). In short, LP2 fractions were purified form both <italic>Slc6a17</italic>-KO +/+ and +/- mice, with the final step centrifuged in 230,000 × <italic>g</italic> instead of 165,000 × <italic>g</italic>. Purified LP2 were stored in –80°C for long-term storage. SVs were further purified by immunoisolation with the anti-Syp antibody coupled to magnetic protein G beads incubated with resuspended LP2 fraction for 2 hr at 4°C (LP2 should be repeatedly passed through 28 gauge needles to be fully resuspended). After six washes in PBS, SVs were magnetically separated and dissociated form beads by adding lysis buffer [10% SDS in 100 mM triethyl ammonium bicarbonate (TEAB)] to samples. Beads were heated in 70°C for 10 min to fully dissolve proteins and then centrifuged 10 min at 16,000 × <italic>g</italic> to remove beads. Protein concentrations were determined by BCA kits (23227, Thermo Scientific) to ensure the total proteins between 50 and 100 µg. Equal amounts of proteins were transferred into new tubes and adjusted to 100 µl with 100 mM TEAB. 5 µl 200 mM TCEP (3,3',3''-phosphinetriyltripropanoic acid) was added and incubated in 55°C for 1 hr. Then 5 µl freshly prepare 375 mM iodoacetamide were added to the samples and incubated for 30 min in dark environment at room temperature. Following addition of six volumes (~600 µl) of pre-chilled (–20°C) acetone, proteins were precipitated overnight at –20°C. Next day, samples were centrifuged at 8000 × <italic>g</italic> for 10 min at 4°C to precipitate proteins. After acetone removal, 100 µl of 100 mM TEAB were added to resuspend proteins. Trypsin was added at 2.5 µg per sample and incubated at 37°C. Then freshly made TMT Label Reagents (0.8 mg/41 µl anhydrous acetonitrile) were added to samples and incubated for 1 hr at room temperature. 8 µl 5% hydroxylamine were added to the samples and incubated for 15 min to quench the reaction. Equal amounts of each sample were combined in a new centrifuge tube and labeled peptides dried in SpeedVac. Pierce High pH Reversed-Phase Peptide Fractionation Kit (84868, Thermo Scientific) were used to clean up and fractionate TMT-labeled peptides before LC-MS/MS. Peptides were identified and analyzed by the Proteomic Center of PKU.</p></sec><sec id="s4-15"><title>Statistical analyses</title><p>For statistical comparisons of two groups, we used the nonparametric Mann–Whitney test to compare two columns of data. For comparisons of more than two groups, we used the one-way ANOVA Brown–Forsythe ANOVA test, and Dunnett’s T3 multiple-comparisons test. We used two-way ANOVA with Tukey’s multiple-comparisons test for multiple factor comparison. An α level of 0.05 (two-tailed) was set for significance. All statistical analysis was done using Prism 8 (GraphPad Software).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Methodology</p></fn><fn fn-type="con" id="con9"><p>Resources, Supervision, Project administration</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal procedures were approved by the Animal Center of Peking University and Animal Care and Use Committee of the Chinese Institute for Brain Research (CIBR). Experiments were carried out in accordance with the guidelines of Institutional Animal Care and Use Committee (IACUC) of Peking University (LSC-RaoY-8) and CIBR (CIBR-IACUC-006).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Sequence information file for AAV plasmid used in this article.</title><p>pAAV-hSyn-SLC6A17-APEX2-WPRE-pA, pAAV-hSyn-SLC6A17-HA-WPRE-pA, pAAV-hSyn-SLC6A17G162R-HA-WPRE-pA, and pAAV-hSyn-DIO-Syp-HA-WPRE-pA-U6-3-t::gRNA WPRE-pA. Sequence information file for pAAV-hSyn-SLC6A17-APEX2-WPRE-pA.</p></caption><media xlink:href="elife-86972-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Summarize table for Slc6a17 gene expression in <italic>Slc6a17</italic><sup>-2A-CreERT2</sup> mice.</title><p>Sequence information file for pAAV-hSyn-SLC6A17-HA-WPRE-pA.</p></caption><media xlink:href="elife-86972-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-86972-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files; Source Data files have been provided for Figures 2, 3, 4, 5, 6, 7, 8, 9, 10, Figure 2-figure supplement 1, Figure 2-figure supplement 2, Figure 3-figure supplement 1, Figure 3-figure supplement 2, Figure 4-figure supplement 1, Figure 5-figure supplement 1, Figure 7-figure supplement 1, and Figure 9-figure supplement 1.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We are grateful to CIBR, Peking-Tsinghua Center for Life Sciences, Shenzhen Bay Laboratory, CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-015), Changping Laboratory for support. We thank the Proteomics Core, EM Core in National Center for Protein Sciences at Peking University for technical support.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Remaileh</surname><given-names>M</given-names></name><name><surname>Wyant</surname><given-names>GA</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Laqtom</surname><given-names>NN</given-names></name><name><surname>Abbasi</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>SH</given-names></name><name><surname>Freinkman</surname><given-names>E</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Lysosomal metabolomics reveals V-Atpase- and mTOR-dependent regulation of amino acid efflux from Lysosomes</article-title><source>Science</source><volume>358</volume><fpage>807</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1126/science.aan6298</pub-id><pub-id pub-id-type="pmid">29074583</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahier</surname><given-names>A</given-names></name><name><surname>Jarriault</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Simultaneous expression of multiple proteins under a single promoter in <italic>Caenorhabditis elegans</italic> via a versatile 2A-based Toolkit</article-title><source>Genetics</source><volume>196</volume><fpage>605</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1534/genetics.113.160846</pub-id><pub-id pub-id-type="pmid">24361941</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bak</surname><given-names>LK</given-names></name><name><surname>Schousboe</surname><given-names>A</given-names></name><name><surname>Waagepetersen</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The glutamate/GABA-Glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer</article-title><source>Journal of Neurochemistry</source><volume>98</volume><fpage>641</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03913.x</pub-id><pub-id pub-id-type="pmid">16787421</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellocchio</surname><given-names>EE</given-names></name><name><surname>Reimer</surname><given-names>RJ</given-names></name><name><surname>Fremeau</surname><given-names>RT</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Uptake of glutamate into synaptic Vesicles by an inorganic phosphate transporter</article-title><source>Science</source><volume>289</volume><fpage>957</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1126/science.289.5481.957</pub-id><pub-id pub-id-type="pmid">10938000</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>AM</given-names></name><name><surname>Quastel</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>Locations of amino acids in brain slices from the rat. Tetrodotoxin-sensitive release of amino acids</article-title><source>The Biochemical Journal</source><volume>128</volume><fpage>631</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1042/bj1280631</pub-id><pub-id pub-id-type="pmid">4634833</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bevins</surname><given-names>RA</given-names></name><name><surname>Besheer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'</article-title><source>Nature Protocols</source><volume>1</volume><fpage>1306</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.205</pub-id><pub-id pub-id-type="pmid">17406415</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blakely</surname><given-names>RD</given-names></name><name><surname>Berson</surname><given-names>HE</given-names></name><name><surname>Fremeau</surname><given-names>RT</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name><name><surname>Peek</surname><given-names>MM</given-names></name><name><surname>Prince</surname><given-names>HK</given-names></name><name><surname>Bradley</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Cloning and expression of a functional serotonin transporter from rat brain</article-title><source>Nature</source><volume>354</volume><fpage>66</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/354066a0</pub-id><pub-id pub-id-type="pmid">1944572</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blakely</surname><given-names>RD</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Vesicular and plasma membrane transporters for neurotransmitters</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a005595</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a005595</pub-id><pub-id pub-id-type="pmid">22199021</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borden</surname><given-names>LA</given-names></name><name><surname>Murali Dhar</surname><given-names>TG</given-names></name><name><surname>Smith</surname><given-names>KE</given-names></name><name><surname>Weinshank</surname><given-names>RL</given-names></name><name><surname>Branchek</surname><given-names>TA</given-names></name><name><surname>Gluchowski</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Tiagabine, SK&amp;F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1</article-title><source>European Journal of Pharmacology</source><volume>269</volume><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/0922-4106(94)90089-2</pub-id><pub-id pub-id-type="pmid">7851497</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyken</surname><given-names>J</given-names></name><name><surname>Grønborg</surname><given-names>M</given-names></name><name><surname>Riedel</surname><given-names>D</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name><name><surname>Chua</surname><given-names>JJE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular profiling of synaptic Vesicle docking sites reveals novel proteins but few differences between glutamatergic and GABAergic synapses</article-title><source>Neuron</source><volume>78</volume><fpage>285</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2013.02.027</pub-id><pub-id pub-id-type="pmid">23622064</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradberry</surname><given-names>MM</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>McKetney</surname><given-names>JM</given-names></name><name><surname>Vestling</surname><given-names>MM</given-names></name><name><surname>Coon</surname><given-names>JJ</given-names></name><name><surname>Chapman</surname><given-names>ER</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Rapid and gentle Immunopurification of brain synaptic Vesicles</article-title><source>The Journal of Neuroscience</source><volume>42</volume><fpage>3512</fpage><lpage>3522</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2521-21.2022</pub-id><pub-id pub-id-type="pmid">35296545</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bröer</surname><given-names>A</given-names></name><name><surname>Wagner</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name><name><surname>Bröer</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Neutral amino acid transporter Asct2 displays substrate-induced Na+ exchange and a substrate-Gated anion Conductance</article-title><source>The Biochemical Journal</source><volume>346 Pt 3</volume><fpage>705</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">10698697</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bröer</surname><given-names>S</given-names></name><name><surname>Brookes</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Transfer of Glutamine between Astrocytes and neurons</article-title><source>Journal of Neurochemistry</source><volume>77</volume><fpage>705</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2001.00322.x</pub-id><pub-id pub-id-type="pmid">11331400</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bröer</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The Slc6 orphans are forming a family of amino acid transporters</article-title><source>Neurochemistry International</source><volume>48</volume><fpage>559</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2005.11.021</pub-id><pub-id pub-id-type="pmid">16540203</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>PM</given-names></name><name><surname>Mehl</surname><given-names>E</given-names></name><name><surname>Cameron</surname><given-names>PL</given-names></name><name><surname>Maycox</surname><given-names>PR</given-names></name><name><surname>Baumert</surname><given-names>M</given-names></name><name><surname>Lottspeich</surname><given-names>F</given-names></name><name><surname>De Camilli</surname><given-names>P</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Synaptic Vesicles Immunoisolated from rat cerebral cortex contain high levels of glutamate</article-title><source>Neuron</source><volume>3</volume><fpage>715</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(89)90240-7</pub-id><pub-id pub-id-type="pmid">2577130</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>PM</given-names></name><name><surname>Hell</surname><given-names>J</given-names></name><name><surname>Mehl</surname><given-names>E</given-names></name><name><surname>Krasel</surname><given-names>C</given-names></name><name><surname>Lottspeich</surname><given-names>F</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>GABA and glycine in synaptic Vesicles: storage and transport characteristics</article-title><source>Neuron</source><volume>7</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(91)90267-4</pub-id><pub-id pub-id-type="pmid">1678614</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KY</given-names></name><name><surname>Jang</surname><given-names>MJ</given-names></name><name><surname>Yoo</surname><given-names>BB</given-names></name><name><surname>Greenbaum</surname><given-names>A</given-names></name><name><surname>Ravi</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>WL</given-names></name><name><surname>Sánchez-Guardado</surname><given-names>L</given-names></name><name><surname>Lois</surname><given-names>C</given-names></name><name><surname>Mazmanian</surname><given-names>SK</given-names></name><name><surname>Deverman</surname><given-names>BE</given-names></name><name><surname>Gradinaru</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Engineered Aavs for efficient noninvasive gene delivery to the central and peripheral nervous systems</article-title><source>Nature Neuroscience</source><volume>20</volume><fpage>1172</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1038/nn.4593</pub-id><pub-id pub-id-type="pmid">28671695</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chantranupong</surname><given-names>L</given-names></name><name><surname>Saulnier</surname><given-names>JL</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Pacold</surname><given-names>ME</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Rapid purification and Metabolomic profiling of synaptic Vesicles from mammalian brain</article-title><source>eLife</source><volume>9</volume><elocation-id>e59699</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.59699</pub-id><pub-id pub-id-type="pmid">33043885</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhry</surname><given-names>FA</given-names></name><name><surname>Reimer</surname><given-names>RJ</given-names></name><name><surname>Krizaj</surname><given-names>D</given-names></name><name><surname>Barber</surname><given-names>D</given-names></name><name><surname>Storm-Mathisen</surname><given-names>J</given-names></name><name><surname>Copenhagen</surname><given-names>DR</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Molecular analysis of system N suggests novel physiological roles in nitrogen metabolism and synaptic transmission</article-title><source>Cell</source><volume>99</volume><fpage>769</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81674-8</pub-id><pub-id pub-id-type="pmid">10619430</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhry</surname><given-names>FA</given-names></name><name><surname>Reimer</surname><given-names>RJ</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The Glutamine commute: take the N line and transfer to the A</article-title><source>The Journal of Cell Biology</source><volume>157</volume><fpage>349</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1083/jcb.200201070</pub-id><pub-id pub-id-type="pmid">11980913</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>KO</given-names></name><name><surname>Hunt</surname><given-names>CA</given-names></name><name><surname>Kennedy</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The rat brain postsynaptic density fraction contains a Homolog of the <italic>Drosophila</italic> discs-large tumor Suppressor protein</article-title><source>Neuron</source><volume>9</volume><fpage>929</fpage><lpage>942</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(92)90245-9</pub-id><pub-id pub-id-type="pmid">1419001</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cidon</surname><given-names>S</given-names></name><name><surname>Sihra</surname><given-names>TS</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Characterization of a H+-Atpase in rat brain synaptic vesicles. Coupling to L-glutamate transport</article-title><source>The Journal of Biological Chemistry</source><volume>264</volume><fpage>8281</fpage><lpage>8288</lpage><pub-id pub-id-type="pmid">2566604</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>JA</given-names></name><name><surname>Deutch</surname><given-names>AY</given-names></name><name><surname>Gallipoli</surname><given-names>PZ</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Functional expression and CNS distribution of a beta-alanine-sensitive neuronal GABA transporter</article-title><source>Neuron</source><volume>9</volume><fpage>337</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(92)90172-a</pub-id><pub-id pub-id-type="pmid">1497897</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contrepois</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Optimized Analytical procedures for the untargeted Metabolomic profiling of human urine and plasma by combining hydrophilic interaction (HILIC) and reverse-phase liquid chromatography (RPLC)-Mass Spectrometry</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>14</volume><fpage>1684</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1074/mcp.M114.046508</pub-id><pub-id pub-id-type="pmid">25787789</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>RW</given-names></name><name><surname>Rossano</surname><given-names>AJ</given-names></name><name><surname>Macleod</surname><given-names>GT</given-names></name><name><surname>Ganetzky</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Expression of multiple Transgenes from a single construct using viral 2A peptides in <italic>Drosophila</italic></article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e100637</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0100637</pub-id><pub-id pub-id-type="pmid">24945148</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deitmer</surname><given-names>JW</given-names></name><name><surname>Bröer</surname><given-names>A</given-names></name><name><surname>Bröer</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Glutamine efflux from Astrocytes is mediated by multiple pathways</article-title><source>Journal of Neurochemistry</source><volume>87</volume><fpage>127</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01981.x</pub-id><pub-id pub-id-type="pmid">12969260</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Ligt</surname><given-names>J</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>van Bon</surname><given-names>BWM</given-names></name><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Yntema</surname><given-names>HG</given-names></name><name><surname>Kroes</surname><given-names>T</given-names></name><name><surname>Vulto-van Silfhout</surname><given-names>AT</given-names></name><name><surname>Koolen</surname><given-names>DA</given-names></name><name><surname>de Vries</surname><given-names>P</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name><name><surname>del Rosario</surname><given-names>M</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><name><surname>Scheffer</surname><given-names>H</given-names></name><name><surname>de Vries</surname><given-names>BBA</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Vissers</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Diagnostic Exome sequencing in persons with severe intellectual disability</article-title><source>The New England Journal of Medicine</source><volume>367</volume><fpage>1921</fpage><lpage>1929</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1206524</pub-id><pub-id pub-id-type="pmid">23033978</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deverman</surname><given-names>BE</given-names></name><name><surname>Pravdo</surname><given-names>PL</given-names></name><name><surname>Simpson</surname><given-names>BP</given-names></name><name><surname>Kumar</surname><given-names>SR</given-names></name><name><surname>Chan</surname><given-names>KY</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>WL</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Huber</surname><given-names>N</given-names></name><name><surname>Pasca</surname><given-names>SP</given-names></name><name><surname>Gradinaru</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>204</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/nbt.3440</pub-id><pub-id pub-id-type="pmid">26829320</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>el Mestikawy</surname><given-names>S</given-names></name><name><surname>Giros</surname><given-names>B</given-names></name><name><surname>Pohl</surname><given-names>M</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Kingsmore</surname><given-names>SF</given-names></name><name><surname>Seldin</surname><given-names>MF</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Characterization of an atypical member of the Na+/Cl(-)-Dependent transporter family: Chromosomal localization and distribution in GABAergic and glutamatergic neurons in the rat brain</article-title><source>Journal of Neurochemistry</source><volume>62</volume><fpage>445</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1994.62020445.x</pub-id><pub-id pub-id-type="pmid">8294906</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>GJO</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Subcellular fractionation of the brain: preparation of Synaptosomes and synaptic Vesicles</article-title><source>Cold Spring Harbor Protocols</source><volume>2015</volume><fpage>462</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1101/pdb.prot083469</pub-id><pub-id pub-id-type="pmid">25934934</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feil</surname><given-names>R</given-names></name><name><surname>Brocard</surname><given-names>J</given-names></name><name><surname>Mascrez</surname><given-names>B</given-names></name><name><surname>LeMeur</surname><given-names>M</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Ligand-activated site-specific Recombination in mice</article-title><source>PNAS</source><volume>93</volume><fpage>10887</fpage><lpage>10890</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.20.10887</pub-id><pub-id pub-id-type="pmid">8855277</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>J</given-names></name><name><surname>Bancila</surname><given-names>V</given-names></name><name><surname>Mailly</surname><given-names>P</given-names></name><name><surname>Masson</surname><given-names>J</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>El Mestikawy</surname><given-names>S</given-names></name><name><surname>Conrath</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Immunocytochemical evidence of vesicular localization of the orphan transporter Rxt1 in the rat spinal cord</article-title><source>Neuroscience</source><volume>92</volume><fpage>729</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1016/s0306-4522(99)00017-2</pub-id><pub-id pub-id-type="pmid">10408621</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geppert</surname><given-names>M</given-names></name><name><surname>Goda</surname><given-names>Y</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Rosahl</surname><given-names>TW</given-names></name><name><surname>Stevens</surname><given-names>CF</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Synaptotagmin I: a major Ca2+ sensor for transmitter release at a central Synapse</article-title><source>Cell</source><volume>79</volume><fpage>717</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90556-8</pub-id><pub-id pub-id-type="pmid">7954835</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilissen</surname><given-names>C</given-names></name><name><surname>Hehir-Kwa</surname><given-names>JY</given-names></name><name><surname>Thung</surname><given-names>DT</given-names></name><name><surname>van de Vorst</surname><given-names>M</given-names></name><name><surname>van Bon</surname><given-names>BWM</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>Kwint</surname><given-names>M</given-names></name><name><surname>Janssen</surname><given-names>IM</given-names></name><name><surname>Hoischen</surname><given-names>A</given-names></name><name><surname>Schenck</surname><given-names>A</given-names></name><name><surname>Leach</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Tearle</surname><given-names>R</given-names></name><name><surname>Bo</surname><given-names>T</given-names></name><name><surname>Pfundt</surname><given-names>R</given-names></name><name><surname>Yntema</surname><given-names>HG</given-names></name><name><surname>de Vries</surname><given-names>BBA</given-names></name><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Vissers</surname><given-names>LELM</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genome sequencing identifies major causes of severe intellectual disability</article-title><source>Nature</source><volume>511</volume><fpage>344</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1038/nature13394</pub-id><pub-id pub-id-type="pmid">24896178</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giros</surname><given-names>B</given-names></name><name><surname>el Mestikawy</surname><given-names>S</given-names></name><name><surname>Bertrand</surname><given-names>L</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Cloning and functional characterization of a cocaine-sensitive dopamine transporter</article-title><source>FEBS Letters</source><volume>295</volume><fpage>149</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(91)81406-x</pub-id><pub-id pub-id-type="pmid">1765147</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grønborg</surname><given-names>M</given-names></name><name><surname>Pavlos</surname><given-names>NJ</given-names></name><name><surname>Brunk</surname><given-names>I</given-names></name><name><surname>Chua</surname><given-names>JJE</given-names></name><name><surname>Münster-Wandowski</surname><given-names>A</given-names></name><name><surname>Riedel</surname><given-names>D</given-names></name><name><surname>Ahnert-Hilger</surname><given-names>G</given-names></name><name><surname>Urlaub</surname><given-names>H</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quantitative comparison of glutamatergic and GABAergic synaptic Vesicles unveils selectivity for few proteins including Mal2, a novel synaptic Vesicle protein</article-title><source>The Journal of Neuroscience</source><volume>30</volume><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4074-09.2010</pub-id><pub-id pub-id-type="pmid">20053882</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Marth</surname><given-names>JD</given-names></name><name><surname>Orban</surname><given-names>PC</given-names></name><name><surname>Mossmann</surname><given-names>H</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting</article-title><source>Science</source><volume>265</volume><fpage>103</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1126/science.8016642</pub-id><pub-id pub-id-type="pmid">8016642</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guastella</surname><given-names>J</given-names></name><name><surname>Brecha</surname><given-names>N</given-names></name><name><surname>Weigmann</surname><given-names>C</given-names></name><name><surname>Lester</surname><given-names>HA</given-names></name><name><surname>Davidson</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Cloning, expression, and localization of a rat brain high-affinity glycine transporter</article-title><source>PNAS</source><volume>89</volume><fpage>7189</fpage><lpage>7193</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.15.7189</pub-id><pub-id pub-id-type="pmid">1353889</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hägglund</surname><given-names>MGA</given-names></name><name><surname>Hellsten</surname><given-names>SV</given-names></name><name><surname>Bagchi</surname><given-names>S</given-names></name><name><surname>Ljungdahl</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>VCO</given-names></name><name><surname>Winnergren</surname><given-names>S</given-names></name><name><surname>Stephansson</surname><given-names>O</given-names></name><name><surname>Rumaks</surname><given-names>J</given-names></name><name><surname>Svirskis</surname><given-names>S</given-names></name><name><surname>Klusa</surname><given-names>V</given-names></name><name><surname>Schiöth</surname><given-names>HB</given-names></name><name><surname>Fredriksson</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Characterization of the Transporterb0At3 (Slc6A17) in the rodent central nervous system</article-title><source>BMC Neuroscience</source><volume>14</volume><elocation-id>54</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2202-14-54</pub-id><pub-id pub-id-type="pmid">23672601</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdan</surname><given-names>FF</given-names></name><name><surname>Srour</surname><given-names>M</given-names></name><name><surname>Capo-Chichi</surname><given-names>JM</given-names></name><name><surname>Daoud</surname><given-names>H</given-names></name><name><surname>Nassif</surname><given-names>C</given-names></name><name><surname>Patry</surname><given-names>L</given-names></name><name><surname>Massicotte</surname><given-names>C</given-names></name><name><surname>Ambalavanan</surname><given-names>A</given-names></name><name><surname>Spiegelman</surname><given-names>D</given-names></name><name><surname>Diallo</surname><given-names>O</given-names></name><name><surname>Henrion</surname><given-names>E</given-names></name><name><surname>Dionne-Laporte</surname><given-names>A</given-names></name><name><surname>Fougerat</surname><given-names>A</given-names></name><name><surname>Pshezhetsky</surname><given-names>AV</given-names></name><name><surname>Venkateswaran</surname><given-names>S</given-names></name><name><surname>Rouleau</surname><given-names>GA</given-names></name><name><surname>Michaud</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>De Novo mutations in moderate or severe intellectual disability</article-title><source>PLOS Genetics</source><volume>10</volume><elocation-id>e1004772</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004772</pub-id><pub-id pub-id-type="pmid">25356899</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensley</surname><given-names>CT</given-names></name><name><surname>Wasti</surname><given-names>AT</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Glutamine and cancer: cell biology, physiology, and clinical opportunities</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>3678</fpage><lpage>3684</lpage><pub-id pub-id-type="doi">10.1172/JCI69600</pub-id><pub-id pub-id-type="pmid">23999442</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hitti</surname><given-names>FL</given-names></name><name><surname>Siegelbaum</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The hippocampal Ca2 region is essential for social memory</article-title><source>Nature</source><volume>508</volume><fpage>88</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1038/nature13028</pub-id><pub-id pub-id-type="pmid">24572357</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>BJ</given-names></name><name><surname>Mezey</surname><given-names>E</given-names></name><name><surname>Brownstein</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Cloning of a serotonin transporter affected by antidepressants</article-title><source>Science</source><volume>254</volume><fpage>579</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1126/science.1948036</pub-id><pub-id pub-id-type="pmid">1948036</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Kahrizi</surname><given-names>K</given-names></name><name><surname>Musante</surname><given-names>L</given-names></name><name><surname>Fattahi</surname><given-names>Z</given-names></name><name><surname>Herwig</surname><given-names>R</given-names></name><name><surname>Hosseini</surname><given-names>M</given-names></name><name><surname>Oppitz</surname><given-names>C</given-names></name><name><surname>Abedini</surname><given-names>SS</given-names></name><name><surname>Suckow</surname><given-names>V</given-names></name><name><surname>Larti</surname><given-names>F</given-names></name><name><surname>Beheshtian</surname><given-names>M</given-names></name><name><surname>Lipkowitz</surname><given-names>B</given-names></name><name><surname>Akhtarkhavari</surname><given-names>T</given-names></name><name><surname>Mehvari</surname><given-names>S</given-names></name><name><surname>Otto</surname><given-names>S</given-names></name><name><surname>Mohseni</surname><given-names>M</given-names></name><name><surname>Arzhangi</surname><given-names>S</given-names></name><name><surname>Jamali</surname><given-names>P</given-names></name><name><surname>Mojahedi</surname><given-names>F</given-names></name><name><surname>Taghdiri</surname><given-names>M</given-names></name><name><surname>Papari</surname><given-names>E</given-names></name><name><surname>Soltani Banavandi</surname><given-names>MJ</given-names></name><name><surname>Akbari</surname><given-names>S</given-names></name><name><surname>Tonekaboni</surname><given-names>SH</given-names></name><name><surname>Dehghani</surname><given-names>H</given-names></name><name><surname>Ebrahimpour</surname><given-names>MR</given-names></name><name><surname>Bader</surname><given-names>I</given-names></name><name><surname>Davarnia</surname><given-names>B</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Khodaei</surname><given-names>H</given-names></name><name><surname>Albrecht</surname><given-names>B</given-names></name><name><surname>Azimi</surname><given-names>S</given-names></name><name><surname>Zirn</surname><given-names>B</given-names></name><name><surname>Bastami</surname><given-names>M</given-names></name><name><surname>Wieczorek</surname><given-names>D</given-names></name><name><surname>Bahrami</surname><given-names>G</given-names></name><name><surname>Keleman</surname><given-names>K</given-names></name><name><surname>Vahid</surname><given-names>LN</given-names></name><name><surname>Tzschach</surname><given-names>A</given-names></name><name><surname>Gärtner</surname><given-names>J</given-names></name><name><surname>Gillessen-Kaesbach</surname><given-names>G</given-names></name><name><surname>Varaghchi</surname><given-names>JR</given-names></name><name><surname>Timmermann</surname><given-names>B</given-names></name><name><surname>Pourfatemi</surname><given-names>F</given-names></name><name><surname>Jankhah</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Nikuei</surname><given-names>P</given-names></name><name><surname>Kalscheuer</surname><given-names>VM</given-names></name><name><surname>Oladnabi</surname><given-names>M</given-names></name><name><surname>Wienker</surname><given-names>TF</given-names></name><name><surname>Ropers</surname><given-names>H-H</given-names></name><name><surname>Najmabadi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genetics of intellectual disability in consanguineous families</article-title><source>Molecular Psychiatry</source><volume>24</volume><fpage>1027</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1038/s41380-017-0012-2</pub-id><pub-id pub-id-type="pmid">29302074</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huttner</surname><given-names>WB</given-names></name><name><surname>Schiebler</surname><given-names>W</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name><name><surname>De Camilli</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Synapsin I (protein I), a nerve terminal-specific Phosphoprotein. III. its association with synaptic Vesicles studied in a highly purified synaptic Vesicle preparation</article-title><source>The Journal of Cell Biology</source><volume>96</volume><fpage>1374</fpage><lpage>1388</lpage><pub-id pub-id-type="doi">10.1083/jcb.96.5.1374</pub-id><pub-id pub-id-type="pmid">6404912</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Indra</surname><given-names>AK</given-names></name><name><surname>Warot</surname><given-names>X</given-names></name><name><surname>Brocard</surname><given-names>J</given-names></name><name><surname>Bornert</surname><given-names>JM</given-names></name><name><surname>Xiao</surname><given-names>JH</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Temporally-controlled site-specific Mutagenesis in the basal layer of the epidermis: comparison of the Recombinase activity of the tamoxifen-inducible CRE-ER(T) and CRE-ER(T2) Recombinases</article-title><source>Nucleic Acids Research</source><volume>27</volume><fpage>4324</fpage><lpage>4327</lpage><pub-id pub-id-type="doi">10.1093/nar/27.22.4324</pub-id><pub-id pub-id-type="pmid">10536138</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iqbal</surname><given-names>Z</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>Papon</surname><given-names>M-A</given-names></name><name><surname>Musante</surname><given-names>L</given-names></name><name><surname>Benevento</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Venselaar</surname><given-names>H</given-names></name><name><surname>Wissink-Lindhout</surname><given-names>WM</given-names></name><name><surname>Vulto-van Silfhout</surname><given-names>AT</given-names></name><name><surname>Vissers</surname><given-names>LELM</given-names></name><name><surname>de Brouwer</surname><given-names>APM</given-names></name><name><surname>Marouillat</surname><given-names>S</given-names></name><name><surname>Wienker</surname><given-names>TF</given-names></name><name><surname>Ropers</surname><given-names>HH</given-names></name><name><surname>Kahrizi</surname><given-names>K</given-names></name><name><surname>Nadif Kasri</surname><given-names>N</given-names></name><name><surname>Najmabadi</surname><given-names>H</given-names></name><name><surname>Laumonnier</surname><given-names>F</given-names></name><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>van Bokhoven</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Homozygous Slc6A17 mutations cause Autosomal-Recessive intellectual disability with progressive tremor, speech impairment, and behavioral problems</article-title><source>American Journal of Human Genetics</source><volume>96</volume><fpage>386</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2015.01.010</pub-id><pub-id pub-id-type="pmid">25704603</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahn</surname><given-names>R</given-names></name><name><surname>Schiebler</surname><given-names>W</given-names></name><name><surname>Ouimet</surname><given-names>C</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>A 38,000-Dalton membrane protein (P38) present in synaptic Vesicles</article-title><source>PNAS</source><volume>82</volume><fpage>4137</fpage><lpage>4141</lpage><pub-id pub-id-type="doi">10.1073/pnas.82.12.4137</pub-id><pub-id pub-id-type="pmid">3923488</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jursky</surname><given-names>F</given-names></name><name><surname>Nelson</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Developmental expression of the neurotransmitter transporter Gat3</article-title><source>Journal of Neuroscience Research</source><volume>55</volume><fpage>394</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4547(19990201)55:3&lt;394::AID-JNR14&gt;3.0.CO;2-E</pub-id><pub-id pub-id-type="pmid">10348670</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachidian</surname><given-names>P</given-names></name><name><surname>Masson</surname><given-names>J</given-names></name><name><surname>Aïdouni</surname><given-names>Z</given-names></name><name><surname>Gaspar</surname><given-names>P</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>El Mestikawy</surname><given-names>S</given-names></name><name><surname>Kerkerian-Le Goff</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The &quot;orphan&quot; Na+/Cl(-)-Dependent transporter, Rxt1, is primarily localized within nerve endings of cortical origin in the rat striatum</article-title><source>Journal of Neurochemistry</source><volume>73</volume><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0730623.x</pub-id><pub-id pub-id-type="pmid">10428058</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>Y</given-names></name><name><surname>Segawa</surname><given-names>H</given-names></name><name><surname>Miyamoto</surname><given-names>K i</given-names></name><name><surname>Uchino</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>E</given-names></name><name><surname>Endou</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (Cd98)</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>23629</fpage><lpage>23632</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.37.23629</pub-id><pub-id pub-id-type="pmid">9726963</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Windpassinger</surname><given-names>C</given-names></name><name><surname>Badar</surname><given-names>M</given-names></name><name><surname>Nawaz</surname><given-names>Z</given-names></name><name><surname>Mohammad</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The molecular Genetics of Autosomal Recessive Nonsyndromic intellectual disability: a mutational continuum and future recommendations</article-title><source>Annals of Human Genetics</source><volume>80</volume><fpage>342</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1111/ahg.12176</pub-id><pub-id pub-id-type="pmid">27870114</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilty</surname><given-names>JE</given-names></name><name><surname>Lorang</surname><given-names>D</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Cloning and expression of a cocaine-sensitive rat dopamine transporter</article-title><source>Science</source><volume>254</volume><fpage>578</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1126/science.1948035</pub-id><pub-id pub-id-type="pmid">1948035</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolodziej</surname><given-names>PA</given-names></name><name><surname>Young</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Epitope tagging and protein surveillance</article-title><source>Methods in Enzymology</source><volume>194</volume><fpage>508</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1016/0076-6879(91)94038-e</pub-id><pub-id pub-id-type="pmid">1706460</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouser</surname><given-names>M</given-names></name><name><surname>Speed</surname><given-names>HE</given-names></name><name><surname>Dewey</surname><given-names>CM</given-names></name><name><surname>Reimers</surname><given-names>JM</given-names></name><name><surname>Widman</surname><given-names>AJ</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Jaramillo</surname><given-names>TC</given-names></name><name><surname>Bangash</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Worley</surname><given-names>PF</given-names></name><name><surname>Powell</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Loss of predominant Shank3 Isoforms results in hippocampus-dependent impairments in behavior and synaptic transmission</article-title><source>The Journal of Neuroscience</source><volume>33</volume><fpage>18448</fpage><lpage>18468</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3017-13.2013</pub-id><pub-id pub-id-type="pmid">24259569</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kristensen</surname><given-names>AS</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Jørgensen</surname><given-names>TN</given-names></name><name><surname>Sørensen</surname><given-names>L</given-names></name><name><surname>Eriksen</surname><given-names>J</given-names></name><name><surname>Loland</surname><given-names>CJ</given-names></name><name><surname>Strømgaard</surname><given-names>K</given-names></name><name><surname>Gether</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Slc6 neurotransmitter transporters: structure, function, and regulation</article-title><source>Pharmacological Reviews</source><volume>63</volume><fpage>585</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1124/pr.108.000869</pub-id><pub-id pub-id-type="pmid">21752877</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>SS</given-names></name><name><surname>Martell</surname><given-names>JD</given-names></name><name><surname>Kamer</surname><given-names>KJ</given-names></name><name><surname>Deerinck</surname><given-names>TJ</given-names></name><name><surname>Ellisman</surname><given-names>MH</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Ting</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Directed evolution of Apex2 for electron microscopy and proximity labeling</article-title><source>Nature Methods</source><volume>12</volume><fpage>51</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3179</pub-id><pub-id pub-id-type="pmid">25419960</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lelieveld</surname><given-names>SH</given-names></name><name><surname>Reijnders</surname><given-names>MRF</given-names></name><name><surname>Pfundt</surname><given-names>R</given-names></name><name><surname>Yntema</surname><given-names>HG</given-names></name><name><surname>Kamsteeg</surname><given-names>EJ</given-names></name><name><surname>de Vries</surname><given-names>P</given-names></name><name><surname>de Vries</surname><given-names>BBA</given-names></name><name><surname>Willemsen</surname><given-names>MH</given-names></name><name><surname>Kleefstra</surname><given-names>T</given-names></name><name><surname>Löhner</surname><given-names>K</given-names></name><name><surname>Vreeburg</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>SJC</given-names></name><name><surname>van der Burgt</surname><given-names>I</given-names></name><name><surname>Bongers</surname><given-names>E</given-names></name><name><surname>Stegmann</surname><given-names>APA</given-names></name><name><surname>Rump</surname><given-names>P</given-names></name><name><surname>Rinne</surname><given-names>T</given-names></name><name><surname>Nelen</surname><given-names>MR</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Vissers</surname><given-names>L</given-names></name><name><surname>Brunner</surname><given-names>HG</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability</article-title><source>Nature Neuroscience</source><volume>19</volume><fpage>1194</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1038/nn.4352</pub-id><pub-id pub-id-type="pmid">27479843</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leube</surname><given-names>RE</given-names></name><name><surname>Kaiser</surname><given-names>P</given-names></name><name><surname>Seiter</surname><given-names>A</given-names></name><name><surname>Zimbelmann</surname><given-names>R</given-names></name><name><surname>Franke</surname><given-names>WW</given-names></name><name><surname>Rehm</surname><given-names>H</given-names></name><name><surname>Knaus</surname><given-names>P</given-names></name><name><surname>Prior</surname><given-names>P</given-names></name><name><surname>Betz</surname><given-names>H</given-names></name><name><surname>Reinke</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Synaptophysin: molecular organization and mRNA expression as determined from Cloned cDNA</article-title><source>The EMBO Journal</source><volume>6</volume><fpage>3261</fpage><lpage>3268</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1987.tb02644.x</pub-id><pub-id pub-id-type="pmid">3123215</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Link</surname><given-names>E</given-names></name><name><surname>Edelmann</surname><given-names>L</given-names></name><name><surname>Chou</surname><given-names>JH</given-names></name><name><surname>Binz</surname><given-names>T</given-names></name><name><surname>Yamasaki</surname><given-names>S</given-names></name><name><surname>Eisel</surname><given-names>U</given-names></name><name><surname>Baumert</surname><given-names>M</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Niemann</surname><given-names>H</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Tetanus toxin action: inhibition of neurotransmitter release linked to Synaptobrevin proteolysis</article-title><source>Biochemical and Biophysical Research Communications</source><volume>189</volume><fpage>1017</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/0006-291x(92)92305-h</pub-id><pub-id pub-id-type="pmid">1361727</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>QR</given-names></name><name><surname>Mandiyan</surname><given-names>S</given-names></name><name><surname>López-Corcuera</surname><given-names>B</given-names></name><name><surname>Nelson</surname><given-names>H</given-names></name><name><surname>Nelson</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>A rat brain cDNA Encoding the neurotransmitter transporter with an unusual structure</article-title><source>FEBS Letters</source><volume>315</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(93)81145-p</pub-id><pub-id pub-id-type="pmid">8093354</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Si</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Chen</surname><given-names>ZF</given-names></name><name><surname>Rao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular regulation of sexual preference revealed by genetic studies of 5-HT in the brains of male mice</article-title><source>Nature</source><volume>472</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/nature09822</pub-id><pub-id pub-id-type="pmid">21441904</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Corcuera</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>QR</given-names></name><name><surname>Mandiyan</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>H</given-names></name><name><surname>Nelson</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Expression of a mouse brain cDNA Encoding novel gamma-aminobutyric acid transporter</article-title><source>The Journal of Biological Chemistry</source><volume>267</volume><fpage>17491</fpage><lpage>17493</lpage><pub-id pub-id-type="pmid">1517200</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><chapter-title>Selective visualization of Caveolae by TEM using Apex2</chapter-title><person-group person-group-type="editor"><name><surname>Blouin</surname><given-names>C</given-names></name></person-group><source>Caveolae</source><publisher-name>Humana</publisher-name><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-0732-9_1</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luque</surname><given-names>JM</given-names></name><name><surname>Jursky</surname><given-names>F</given-names></name><name><surname>Nelson</surname><given-names>N</given-names></name><name><surname>Richards</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Distribution and sites of synthesis of Ntt4, an orphan member of the Na+/Cl(-)-Dependent neurotransmitter transporter family, in the rat CNS</article-title><source>The European Journal of Neuroscience</source><volume>8</volume><fpage>127</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.1996.tb01173.x</pub-id><pub-id pub-id-type="pmid">8713456</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>GM</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>van den Broek</surname><given-names>NJ</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Analysis of cell metabolism using LC-MS and Isotope tracers</article-title><source>Methods in Enzymology</source><volume>561</volume><fpage>171</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2015.05.016</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>B</given-names></name><name><surname>Schäfer</surname><given-names>MKH</given-names></name><name><surname>Erickson</surname><given-names>JD</given-names></name><name><surname>Hediger</surname><given-names>MA</given-names></name><name><surname>Weihe</surname><given-names>E</given-names></name><name><surname>Varoqui</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Functional properties and cellular distribution of the system A Glutamine transporter Snat1 support specialized roles in central neurons</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>23720</fpage><lpage>23730</lpage><pub-id pub-id-type="doi">10.1074/jbc.M212718200</pub-id><pub-id pub-id-type="pmid">12684517</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madisen</surname><given-names>L</given-names></name><name><surname>Zwingman</surname><given-names>TA</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Oh</surname><given-names>SW</given-names></name><name><surname>Zariwala</surname><given-names>HA</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Ng</surname><given-names>LL</given-names></name><name><surname>Palmiter</surname><given-names>RD</given-names></name><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A robust and high-throughput CRE reporting and characterization system for the whole Mouse brain</article-title><source>Nature Neuroscience</source><volume>13</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1038/nn.2467</pub-id><pub-id pub-id-type="pmid">20023653</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martell</surname><given-names>JD</given-names></name><name><surname>Deerinck</surname><given-names>TJ</given-names></name><name><surname>Lam</surname><given-names>SS</given-names></name><name><surname>Ellisman</surname><given-names>MH</given-names></name><name><surname>Ting</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Electron microscopy using the genetically encoded Apex2 tag in cultured mammalian cells</article-title><source>Nature Protocols</source><volume>12</volume><fpage>1792</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.065</pub-id><pub-id pub-id-type="pmid">28796234</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martineau</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><name><surname>Puyal</surname><given-names>J</given-names></name><name><surname>Knolhoff</surname><given-names>AM</given-names></name><name><surname>Dulong</surname><given-names>J</given-names></name><name><surname>Gasnier</surname><given-names>B</given-names></name><name><surname>Klingauf</surname><given-names>J</given-names></name><name><surname>Sweedler</surname><given-names>JV</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name><name><surname>Mothet</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Storage and uptake of D-Serine into Astrocytic synaptic-like Vesicles specify Gliotransmission</article-title><source>The Journal of Neuroscience</source><volume>33</volume><fpage>3413</fpage><lpage>3423</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3497-12.2013</pub-id><pub-id pub-id-type="pmid">23426669</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>J</given-names></name><name><surname>Langlois</surname><given-names>X</given-names></name><name><surname>Lanfumey</surname><given-names>L</given-names></name><name><surname>Gérard</surname><given-names>C</given-names></name><name><surname>Aïdouni</surname><given-names>Z</given-names></name><name><surname>Giros</surname><given-names>B</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>el Mestikawy</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Immunolabeling of the Na+/Cl(-)-Dependent &quot;orphan&quot; transporter Rxt1 in the rat central nervous system</article-title><source>Journal of Neuroscience Research</source><volume>42</volume><fpage>423</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1002/jnr.490420317</pub-id><pub-id pub-id-type="pmid">8583511</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>J</given-names></name><name><surname>Riad</surname><given-names>M</given-names></name><name><surname>Chaudhry</surname><given-names>F</given-names></name><name><surname>Darmon</surname><given-names>M</given-names></name><name><surname>Aïdouni</surname><given-names>Z</given-names></name><name><surname>Conrath</surname><given-names>M</given-names></name><name><surname>Giros</surname><given-names>B</given-names></name><name><surname>Hamon</surname><given-names>M</given-names></name><name><surname>Storm-Mathisen</surname><given-names>J</given-names></name><name><surname>Descarries</surname><given-names>L</given-names></name><name><surname>El Mestikawy</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Unexpected localization of the Na+/Cl--dependent-like orphan transporter, Rxt1, on synaptic Vesicles in the rat central nervous system</article-title><source>The European Journal of Neuroscience</source><volume>11</volume><fpage>1349</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1046/j.1460-9568.1999.00540.x</pub-id><pub-id pub-id-type="pmid">10103130</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maulik</surname><given-names>PK</given-names></name><name><surname>Mascarenhas</surname><given-names>MN</given-names></name><name><surname>Mathers</surname><given-names>CD</given-names></name><name><surname>Dua</surname><given-names>T</given-names></name><name><surname>Saxena</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Prevalence of intellectual disability: a meta-analysis of population-based studies</article-title><source>Research in Developmental Disabilities</source><volume>32</volume><fpage>419</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.ridd.2010.12.018</pub-id><pub-id pub-id-type="pmid">21236634</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michlits</surname><given-names>G</given-names></name><name><surname>Jude</surname><given-names>J</given-names></name><name><surname>Hinterndorfer</surname><given-names>M</given-names></name><name><surname>de Almeida</surname><given-names>M</given-names></name><name><surname>Vainorius</surname><given-names>G</given-names></name><name><surname>Hubmann</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>T</given-names></name><name><surname>Schleiffer</surname><given-names>A</given-names></name><name><surname>Burkard</surname><given-names>TR</given-names></name><name><surname>Fellner</surname><given-names>M</given-names></name><name><surname>Gijsbertsen</surname><given-names>M</given-names></name><name><surname>Traunbauer</surname><given-names>A</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Elling</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function Alleles</article-title><source>Nature Methods</source><volume>17</volume><fpage>708</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-0850-8</pub-id><pub-id pub-id-type="pmid">32514112</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>RG</given-names></name><name><surname>Garrud</surname><given-names>P</given-names></name><name><surname>Rawlins</surname><given-names>JN</given-names></name><name><surname>O’Keefe</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Place navigation impaired in rats with hippocampal-lesions</article-title><source>Nature</source><volume>297</volume><fpage>681</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1038/297681a0</pub-id><pub-id pub-id-type="pmid">7088155</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Developments of a water-maze procedure for studying spatial-learning in the rat</article-title><source>Journal of Neuroscience Methods</source><volume>11</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/0165-0270(84)90007-4</pub-id><pub-id pub-id-type="pmid">6471907</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mu</surname><given-names>FT</given-names></name><name><surname>Callaghan</surname><given-names>JM</given-names></name><name><surname>Steele-Mortimer</surname><given-names>O</given-names></name><name><surname>Stenmark</surname><given-names>H</given-names></name><name><surname>Parton</surname><given-names>RG</given-names></name><name><surname>Campbell</surname><given-names>PL</given-names></name><name><surname>McCluskey</surname><given-names>J</given-names></name><name><surname>Yeo</surname><given-names>JP</given-names></name><name><surname>Tock</surname><given-names>EPC</given-names></name><name><surname>Toh</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Eea1, an early Endosome-associated protein</article-title><source>Journal of Biological Chemistry</source><volume>270</volume><fpage>13503</fpage><lpage>13511</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.22.13503</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottersen</surname><given-names>OP</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Walberg</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Metabolic Compartmentation of glutamate and Glutamine: morphological evidence obtained by quantitative Immunocytochemistry in rat cerebellum</article-title><source>Neuroscience</source><volume>46</volume><fpage>519</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(92)90141-n</pub-id><pub-id pub-id-type="pmid">1347649</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacholczyk</surname><given-names>T</given-names></name><name><surname>Blakely</surname><given-names>RD</given-names></name><name><surname>Amara</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Expression cloning of a Cocaine- and antidepressant-sensitive human noradrenaline transporter</article-title><source>Nature</source><volume>350</volume><fpage>350</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1038/350350a0</pub-id><pub-id pub-id-type="pmid">2008212</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parra</surname><given-names>LA</given-names></name><name><surname>Baust</surname><given-names>T</given-names></name><name><surname>El Mestikawy</surname><given-names>S</given-names></name><name><surname>Quiroz</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>B</given-names></name><name><surname>Haflett</surname><given-names>JM</given-names></name><name><surname>Yao</surname><given-names>JK</given-names></name><name><surname>Torres</surname><given-names>GE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The orphan transporter Rxt1/Ntt4 (Slc6A17) functions as a synaptic Vesicle amino acid transporter selective for Proline, glycine, Leucine, and alanine</article-title><source>Molecular Pharmacology</source><volume>74</volume><fpage>1521</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1124/mol.108.050005</pub-id><pub-id pub-id-type="pmid">18768736</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Paxinos</surname><given-names>G</given-names></name><name><surname>Franklin</surname><given-names>KBJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>Paxinos and Franklin’s the Mouse Brain in Stereotaxic Coordinates</source><publisher-name>Academic Press</publisher-name></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>RG</given-names></name><name><surname>LeDoux</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Differential contribution of amygdala and hippocampus to Cued and Contextual fear conditioning</article-title><source>Behavioral Neuroscience</source><volume>106</volume><fpage>274</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1037//0735-7044.106.2.274</pub-id><pub-id pub-id-type="pmid">1590953</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yim</surname><given-names>MJ</given-names></name><name><surname>Swiech</surname><given-names>L</given-names></name><name><surname>Kempton</surname><given-names>HR</given-names></name><name><surname>Dahlman</surname><given-names>JE</given-names></name><name><surname>Parnas</surname><given-names>O</given-names></name><name><surname>Eisenhaure</surname><given-names>TM</given-names></name><name><surname>Jovanovic</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>DB</given-names></name><name><surname>Jhunjhunwala</surname><given-names>S</given-names></name><name><surname>Heidenreich</surname><given-names>M</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CRISPR-Cas9 Knockin mice for genome editing and cancer modeling</article-title><source>Cell</source><volume>159</volume><fpage>440</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.014</pub-id><pub-id pub-id-type="pmid">25263330</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Port</surname><given-names>F</given-names></name><name><surname>Bullock</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Augmenting CRISPR applications in <italic>Drosophila</italic> with tRNA-flanked sgRNAs</article-title><source>Nature Methods</source><volume>13</volume><fpage>852</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3972</pub-id><pub-id pub-id-type="pmid">27595403</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>CM</given-names></name><name><surname>Schoch</surname><given-names>S</given-names></name><name><surname>Monteggia</surname><given-names>L</given-names></name><name><surname>Barrot</surname><given-names>M</given-names></name><name><surname>Matos</surname><given-names>MF</given-names></name><name><surname>Feldmann</surname><given-names>N</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Nestler</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The Presynaptic active zone protein Rim1Alpha is critical for normal learning and memory</article-title><source>Neuron</source><volume>42</volume><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(04)00146-1</pub-id><pub-id pub-id-type="pmid">15066271</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Neurochemical phenotypes of the afferent and Efferent projections of the Mouse medial Habenula</article-title><source>Neuroscience</source><volume>161</volume><fpage>827</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.03.085</pub-id><pub-id pub-id-type="pmid">19362132</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Lyu</surname><given-names>T</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CDYL deficiency disrupts neuronal migration and increases susceptibility to epilepsy</article-title><source>Cell Reports</source><volume>18</volume><fpage>380</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.043</pub-id><pub-id pub-id-type="pmid">28076783</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>A</given-names></name><name><surname>Wieczorek</surname><given-names>D</given-names></name><name><surname>Graf</surname><given-names>E</given-names></name><name><surname>Wieland</surname><given-names>T</given-names></name><name><surname>Endele</surname><given-names>S</given-names></name><name><surname>Schwarzmayr</surname><given-names>T</given-names></name><name><surname>Albrecht</surname><given-names>B</given-names></name><name><surname>Bartholdi</surname><given-names>D</given-names></name><name><surname>Beygo</surname><given-names>J</given-names></name><name><surname>Di Donato</surname><given-names>N</given-names></name><name><surname>Dufke</surname><given-names>A</given-names></name><name><surname>Cremer</surname><given-names>K</given-names></name><name><surname>Hempel</surname><given-names>M</given-names></name><name><surname>Horn</surname><given-names>D</given-names></name><name><surname>Hoyer</surname><given-names>J</given-names></name><name><surname>Joset</surname><given-names>P</given-names></name><name><surname>Röpke</surname><given-names>A</given-names></name><name><surname>Moog</surname><given-names>U</given-names></name><name><surname>Riess</surname><given-names>A</given-names></name><name><surname>Thiel</surname><given-names>CT</given-names></name><name><surname>Tzschach</surname><given-names>A</given-names></name><name><surname>Wiesener</surname><given-names>A</given-names></name><name><surname>Wohlleber</surname><given-names>E</given-names></name><name><surname>Zweier</surname><given-names>C</given-names></name><name><surname>Ekici</surname><given-names>AB</given-names></name><name><surname>Zink</surname><given-names>AM</given-names></name><name><surname>Rump</surname><given-names>A</given-names></name><name><surname>Meisinger</surname><given-names>C</given-names></name><name><surname>Grallert</surname><given-names>H</given-names></name><name><surname>Sticht</surname><given-names>H</given-names></name><name><surname>Schenck</surname><given-names>A</given-names></name><name><surname>Engels</surname><given-names>H</given-names></name><name><surname>Rappold</surname><given-names>G</given-names></name><name><surname>Schröck</surname><given-names>E</given-names></name><name><surname>Wieacker</surname><given-names>P</given-names></name><name><surname>Riess</surname><given-names>O</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Reis</surname><given-names>A</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Range of genetic mutations associated with severe non-Syndromic sporadic intellectual disability: an Exome sequencing study</article-title><source>Lancet</source><volume>380</volume><fpage>1674</fpage><lpage>1682</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61480-9</pub-id><pub-id pub-id-type="pmid">23020937</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravichandran</surname><given-names>V</given-names></name><name><surname>Chawla</surname><given-names>A</given-names></name><name><surname>Roche</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Identification of a novel Syntaxin- and Synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues</article-title><source>The Journal of Biological Chemistry</source><volume>271</volume><fpage>13300</fpage><lpage>13303</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.23.13300</pub-id><pub-id pub-id-type="pmid">8663154</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reimer</surname><given-names>RJ</given-names></name><name><surname>Chaudhry</surname><given-names>FA</given-names></name><name><surname>Gray</surname><given-names>AT</given-names></name><name><surname>Edwards</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Amino acid transport system A resembles system N in sequence but differs in mechanism</article-title><source>PNAS</source><volume>97</volume><fpage>7715</fpage><lpage>7720</lpage><pub-id pub-id-type="doi">10.1073/pnas.140152797</pub-id><pub-id pub-id-type="pmid">10859363</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitzer</surname><given-names>LJ</given-names></name><name><surname>Wice</surname><given-names>BM</given-names></name><name><surname>Kennell</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Evidence that Glutamine, not sugar, is the major energy source for cultured Hela cells</article-title><source>The Journal of Biological Chemistry</source><volume>254</volume><fpage>2669</fpage><lpage>2676</lpage><pub-id pub-id-type="pmid">429309</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ropers</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Genetics of early onset cognitive impairment</article-title><source>Annual Review of Genomics and Human Genetics</source><volume>11</volume><fpage>161</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1146/annurev-genom-082509-141640</pub-id><pub-id pub-id-type="pmid">20822471</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudnick</surname><given-names>G</given-names></name><name><surname>Krämer</surname><given-names>R</given-names></name><name><surname>Blakely</surname><given-names>RD</given-names></name><name><surname>Murphy</surname><given-names>DL</given-names></name><name><surname>Verrey</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The Slc6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction</article-title><source>Pflugers Archiv</source><volume>466</volume><fpage>25</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1007/s00424-013-1410-1</pub-id><pub-id pub-id-type="pmid">24337881</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>B</given-names></name><name><surname>Henderson</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1</article-title><source>PNAS</source><volume>85</volume><fpage>5166</fpage><lpage>5170</lpage><pub-id pub-id-type="doi">10.1073/pnas.85.14.5166</pub-id><pub-id pub-id-type="pmid">2839833</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavo</surname><given-names>G</given-names></name><name><surname>Benfenati</surname><given-names>F</given-names></name><name><surname>Poulain</surname><given-names>B</given-names></name><name><surname>Rossetto</surname><given-names>O</given-names></name><name><surname>Polverino de Laureto</surname><given-names>P</given-names></name><name><surname>DasGupta</surname><given-names>BR</given-names></name><name><surname>Montecucco</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Tetanus and botulinum-B Neurotoxins block neurotransmitter release by proteolytic cleavage of Synaptobrevin</article-title><source>Nature</source><volume>359</volume><fpage>832</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1038/359832a0</pub-id><pub-id pub-id-type="pmid">1331807</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>S</given-names></name><name><surname>Kitayama</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>CL</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Nanthakumar</surname><given-names>E</given-names></name><name><surname>Gregor</surname><given-names>P</given-names></name><name><surname>Kuhar</surname><given-names>M</given-names></name><name><surname>Uhl</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA</article-title><source>Science</source><volume>254</volume><fpage>576</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1126/science.1948034</pub-id><pub-id pub-id-type="pmid">1948034</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>KE</given-names></name><name><surname>Borden</surname><given-names>LA</given-names></name><name><surname>Hartig</surname><given-names>PR</given-names></name><name><surname>Branchek</surname><given-names>T</given-names></name><name><surname>Weinshank</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Cloning and expression of a glycine transporter reveal Colocalization with NMDA receptors</article-title><source>Neuron</source><volume>8</volume><fpage>927</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1016/0896-6273(92)90207-t</pub-id><pub-id pub-id-type="pmid">1534013</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Lottspeich</surname><given-names>F</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name><name><surname>Mehl</surname><given-names>E</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>A synaptic Vesicle protein with a novel cytoplasmic domain and four Transmembrane regions</article-title><source>Science</source><volume>238</volume><fpage>1142</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1126/science.3120313</pub-id><pub-id pub-id-type="pmid">3120313</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>YH</given-names></name><name><surname>Terashima</surname><given-names>A</given-names></name><name><surname>Petralia</surname><given-names>RS</given-names></name><name><surname>Wenthold</surname><given-names>RJ</given-names></name><name><surname>Isaac</surname><given-names>JTR</given-names></name><name><surname>Roche</surname><given-names>KW</given-names></name><name><surname>Roche</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A neuronal role for SNAP-23 in postsynaptic glutamate receptor trafficking</article-title><source>Nature Neuroscience</source><volume>13</volume><fpage>338</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/nn.2488</pub-id><pub-id pub-id-type="pmid">20118925</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takamori</surname><given-names>S</given-names></name><name><surname>Rhee</surname><given-names>JS</given-names></name><name><surname>Rosenmund</surname><given-names>C</given-names></name><name><surname>Jahn</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons</article-title><source>Nature</source><volume>407</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/35025070</pub-id><pub-id pub-id-type="pmid">11001057</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trichas</surname><given-names>G</given-names></name><name><surname>Begbie</surname><given-names>J</given-names></name><name><surname>Srinivas</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Use of the viral 2A peptide for Bicistronic expression in transgenic mice</article-title><source>BMC Biology</source><volume>6</volume><elocation-id>40</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7007-6-40</pub-id><pub-id pub-id-type="pmid">18793381</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>CJ</given-names></name><name><surname>Garfinkel</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1971">1971</year><article-title>A simulation study of brain compartments. Metabolism of glutamate and related substances in Mouse brain</article-title><source>The Biochemical Journal</source><volume>123</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1042/bj1230211</pub-id><pub-id pub-id-type="pmid">5164952</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varoqui</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>D</given-names></name><name><surname>Ming</surname><given-names>H</given-names></name><name><surname>Erickson</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cloning and functional identification of a neuronal Glutamine transporter</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>4049</fpage><lpage>4054</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.6.4049</pub-id><pub-id pub-id-type="pmid">10660562</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vissers</surname><given-names>L</given-names></name><name><surname>Gilissen</surname><given-names>C</given-names></name><name><surname>Veltman</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genetic studies in intellectual disability and related disorders</article-title><source>Nature Reviews. Genetics</source><volume>17</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1038/nrg3999</pub-id><pub-id pub-id-type="pmid">26503795</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waltl</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mutations in Slc6A17 cause Autosomal-Recessive intellectual disability</article-title><source>Clinical Genetics</source><volume>88</volume><fpage>136</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1111/cge.12610</pub-id><pub-id pub-id-type="pmid">25970702</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>MD</given-names></name><name><surname>Derazi</surname><given-names>S</given-names></name><name><surname>Rossignol</surname><given-names>C</given-names></name><name><surname>Varoqui</surname><given-names>H</given-names></name><name><surname>Erickson</surname><given-names>JD</given-names></name><name><surname>Kilberg</surname><given-names>MS</given-names></name><name><surname>Anderson</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Ontogeny of the neutral amino acid transporter Sat1/Ata1 in rat brain</article-title><source>Brain Research. Developmental Brain Research</source><volume>143</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/s0165-3806(03)00107-x</pub-id><pub-id pub-id-type="pmid">12855186</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wernisch</surname><given-names>S</given-names></name><name><surname>Pennathur</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Evaluation of coverage, retention patterns, and selectivity of seven liquid chromatographic methods for metabolomics</article-title><source>Analytical and Bioanalytical Chemistry</source><volume>408</volume><fpage>6079</fpage><lpage>6091</lpage><pub-id pub-id-type="doi">10.1007/s00216-016-9716-4</pub-id><pub-id pub-id-type="pmid">27370688</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiedenmann</surname><given-names>B</given-names></name><name><surname>Franke</surname><given-names>WW</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Identification and localization of Synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of Presynaptic Vesicles</article-title><source>Cell</source><volume>41</volume><fpage>1017</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(85)80082-9</pub-id><pub-id pub-id-type="pmid">3924408</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>DF</given-names></name><name><surname>Bryant</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>The discs-large tumor Suppressor gene of <italic>Drosophila</italic> Encodes a Guanylate kinase Homolog localized at Septate Junctions</article-title><source>Cell</source><volume>66</volume><fpage>451</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(81)90009-x</pub-id><pub-id pub-id-type="pmid">1651169</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>K</given-names></name><name><surname>Minkenberg</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Boosting CRISPR/Cas9 Multiplex editing capability with the endogenous tRNA-processing system</article-title><source>PNAS</source><volume>112</volume><fpage>3570</fpage><lpage>3575</lpage><pub-id pub-id-type="doi">10.1073/pnas.1420294112</pub-id><pub-id pub-id-type="pmid">25733849</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaia</surname><given-names>KA</given-names></name><name><surname>Reimer</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Synaptic vesicle protein NTT4/XT1 (SLC6A17) catalyzes Na<sup>+</sup>-coupled neutral amino acid transport</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>8439</fpage><lpage>8448</lpage><pub-id pub-id-type="doi">10.1074/jbc.M806407200</pub-id><pub-id pub-id-type="pmid">19147495</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Creek</surname><given-names>DJ</given-names></name><name><surname>Barrett</surname><given-names>MP</given-names></name><name><surname>Blackburn</surname><given-names>G</given-names></name><name><surname>Watson</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Evaluation of coupling reversed phase, aqueous normal phase, and hydrophilic interaction liquid chromatography with Orbitrap mass Spectrometry for Metabolomic studies of human urine</article-title><source>Analytical Chemistry</source><volume>84</volume><fpage>1994</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1021/ac2030738</pub-id><pub-id pub-id-type="pmid">22409530</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Watson</surname><given-names>DG</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Westrop</surname><given-names>GD</given-names></name><name><surname>Coombs</surname><given-names>GH</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Evaluation of mobile phase characteristics on three Zwitterionic columns in hydrophilic interaction liquid chromatography mode for liquid chromatography-high resolution mass Spectrometry based untargeted metabolite profiling of Leishmania parasites</article-title><source>Journal of Chromatography. A</source><volume>1362</volume><fpage>168</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.chroma.2014.08.039</pub-id><pub-id pub-id-type="pmid">25160959</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>SLC6A17</italic></td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NM_001010898.4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Syp</td><td align="left" valign="bottom">GenBank</td><td align="left" valign="bottom">NM_009305.2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (C57BJ/N)</td><td align="left" valign="bottom">Ai14</td><td align="left" valign="bottom">Dr. Hongkui Zeng lab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (C57BJ/N)</td><td align="left" valign="bottom">Rosa26-LSL-Cas9</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="char" char="." valign="bottom">028551</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (C57BJ/N)</td><td align="left" valign="bottom"><italic>Slc6a17</italic><sup>-2A-CreERT2</sup></td><td align="left" valign="bottom">CasGene Biotech (Beijing, China)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (C57BJ/N)</td><td align="left" valign="bottom"><italic>Slc6a17</italic>-KO</td><td align="left" valign="bottom">CasGene Biotech (Beijing, China)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (C57BJ/N)</td><td align="left" valign="bottom"><italic>Slc6a17</italic><sup>-HA-2A-iCre</sup></td><td align="left" valign="bottom">Biocytogen (Beijing, China)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (C57BJ/N)</td><td align="left" valign="bottom"><italic>Slc6a17</italic><sup>P633R</sup></td><td align="left" valign="bottom">Biocytogen (Beijing, China)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV-hSyn-SLC6A17-<break/>APEX2-WPRE-pA (plasmids)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref></td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV-hSyn-SLC6A17-<break/>HA-WPRE-pA (plasmids)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV-hSyn-SLC6A17G<break/>162R-HA-WPRE-pA (plasmids)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pAAV-hSyn-DIO-Syp-HA-WPRE-<break/>pA-U6-3-t::gRNA WPRE-pA (plasmids)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">NEBuilder HiFi DNA Assembly Cloning Kit</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">E5520S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Synaptophysin <break/>(mouse monoclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">101011</td><td align="left" valign="bottom">IP 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Synaptophysin <break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">101 002</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Synaptotagmin 1 (rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">105 008</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-VGLUT 1 (rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">135 302</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Proton ATPase (rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">109 002</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Synaptobrevin 2 (rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">104 202</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-SV2A (rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">119 002</td><td align="left" valign="bottom">IB 1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-VGAT (rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">131 002</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-VGLUT2 (rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">135 402</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-SNAP23 (rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">111 202</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GluN1 (mouse polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">114 011</td><td align="left" valign="bottom">IB 1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-ERC 1b/2 <break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Synaptic System</td><td align="char" char="." valign="bottom">143003</td><td align="left" valign="bottom">IB 1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Synaptophysin <break/>(mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab52636</td><td align="left" valign="bottom">IF 1:500</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 488 Anti-Synaptophysin <break/>(mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab196379</td><td align="left" valign="bottom">IF 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Cathepsin D (rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab75852</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PSMC6 (mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab22639</td><td align="left" valign="bottom">IB 1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GLUT4 (rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab33780</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Transferring receptor (rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab84036</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-M6PR (rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab124767</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LAMP2 (rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">#49067</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-EEA1 (rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">#3288</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-ERp72 (rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">#5033</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Goglin-97 (rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">#12192S</td><td align="left" valign="bottom">IB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GM130 (rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">#12480</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-VDAC (rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">#4661S</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Syntaxin 6 (rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">#2869</td><td align="left" valign="bottom">IB 1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-LC3B (rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">#2775</td><td align="left" valign="bottom">IB 1:2000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-HA (rabbit monoclonal)</td><td align="left" valign="bottom">CST</td><td align="left" valign="bottom">#3724S</td><td align="left" valign="bottom">IB 1:5000<break/>IF 1:200</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PSD95 (mouse monoclonal)</td><td align="left" valign="bottom">NeuroMab</td><td align="char" char="." valign="bottom">75028</td><td align="left" valign="bottom">IB 1:5000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-FLAG M2 HRP (mouse monoclonal)</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">A8592</td><td align="left" valign="bottom">IB 1:5000</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TMT10plex Isobaric Label Reagent Set</td><td align="left" valign="bottom">Thermo Scientific</td><td align="char" char="." valign="bottom">90113</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce High pH Reversed-<break/>Phase Peptide Fractionation Kit</td><td align="left" valign="bottom">Thermo Scientific</td><td align="char" char="." valign="bottom">84868</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce protein G magnetic beads</td><td align="left" valign="bottom">Thermo Scientific</td><td align="char" char="." valign="bottom">88848</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce anti-HA magnetic beads</td><td align="left" valign="bottom">Thermo Scientific</td><td align="char" char="." valign="bottom">88837</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">KO sgRNA1 (5’- <named-content content-type="sequence">CGATGCTCCAGGCCACAAGGAGG</named-content> -3’)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Michlits et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Targeting exon 5</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">KO sgRNA2 (5’-<named-content content-type="sequence">GCCGTGGCAGCATTGGTGTGTGG</named-content> -3’)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Michlits et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Targeting exon 3</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">KO sgRNA3 (5’- <named-content content-type="sequence">TGGGCCTGGGCAACATCTGGAGG</named-content> -3’)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Michlits et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Targeting exon 2</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">3,3-Diaminobenzidine</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">D5905</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Noldus Video Tracking Software</td><td align="left" valign="bottom">Noldus</td><td align="left" valign="bottom">Ethovision XT 15</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism 8</td><td align="left" valign="bottom">GraphPad Software</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">SeQuant ZIC-HILIC column <break/>(150 mm × 2.1 mm, 3.5 μm)</td><td align="left" valign="bottom">Merck Millipore</td><td align="char" char="." valign="bottom">150442</td><td align="left" valign="bottom">HPLC column for chemical detection</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">SeQuant ZIC-pHILIC column <break/>(150 mm × 2.1 mm, 5 μm)</td><td align="left" valign="bottom">Merck Millipore</td><td align="char" char="." valign="bottom">150460</td><td align="left" valign="bottom">HPLC column for chemical detection</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86972.2.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brose</surname><given-names>Nils</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Max Planck Institute of Experimental Medicine</institution><country>Germany</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This study makes a <bold>valuable</bold> contribution to our functional understanding of the atypical amino acid transporter SLC6A177 at nerve cell synapses and the role of SLC6A17 variants in certain forms of intellectual disability. The reported evidence that disease-linked SLC6A17 variants cause behavioral abnormalities is <bold>convincing</bold>. However, corresponding molecular underpinnings, that is, the molecular role of SLC6A17 in synapses and the functional molecular consequences of disease-related SLC6A17 variations, remain unclear because corresponding informative experimental approaches are missing – most importantly direct measurements of the transport activity of SLC6A17 in the various genetic contexts studied. This limits the robustness and validity of key mechanistic conclusions drawn from the present work.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86972.2.sa1</article-id><title-group><article-title>Joint Public Review</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>The molecular composition of synaptic vesicles (SVs) has been defined in substantial detail, but the function of many SV-resident proteins are still unknown. The present study focused on one such protein, the 'orphan' SV-resident transporter SLC6A17. By utilizing sophisticated and extensive mouse genetics and behavioral experiments, the authors provide convincing support for the notion that certain SLC6A17 variants cause intellectual disability (ID) in humans carrying such genetic variations. This is an important and novel finding. Furthermore, the authors propose, based on LC-MS analyses of isolated SVs, that SLC6A17 is responsible for glutamine (Gln) transport into SVs, leading to the provocative idea that Gln functions as a neurotransmitter and that deficits in Gln transport into SVs by SLC6A17 represents a key pathogenetic mechanism in human ID patients carrying variants of the SLC6A17 gene.</p><p>This latter aspect of the present paper is not adequately supported by the experimental evidence so that the main conceptual claims of the study appear insufficiently justified at this juncture. Key weaknesses are as follows:</p><p>A. Detection of Gln, along with classical neurotransmitters such as glutamate, GABA, or ACh, in isolated SV fractions does not prove that Gln is transported into SVs by active transport. Gln is quite abundant in extracellular compartments. Its appearance in SV samples can therefore also be explained by trapping in SVs during endocytosis, presence in other - contaminating - organelles, binding to membrane surfaces, and other processes. Direct assays of Gln uptake into SVs, which have the potential to stringently test key postulates of the authors, are lacking.</p><p>B. The authors generated multiple potentially very useful genetic tools and models. However, the validation of these models is incomplete. Most importantly, it remains unclear whether the different mutations affect SLC6A17 expression levels, subcellular localization, or the expression and trafficking of other SV and synapse components.</p><p>C. Apart from the caveats mentioned above regarding Gln uptake into SVs, the data interpretation provided by the authors lacks stringency with respect to the biophysics of plasma membrane and SV transporters.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86972.2.sa2</article-id><title-group><article-title>Author Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Xiaobo</given-names></name><role specific-use="author">Author</role><aff><institution>Chinese Institute for Brain Research</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Jiemin</given-names></name><role specific-use="author">Author</role><aff><institution>Tsinghua University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Bian</surname><given-names>Xiling</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Sulin</given-names></name><role specific-use="author">Author</role><aff><institution>Shenzhen Bay Laboratory</institution><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Sihan</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liang</surname><given-names>Wenjun</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Lifen</given-names></name><role specific-use="author">Author</role><aff><institution>Shenzhen Bay Laboratory</institution><addr-line><named-content content-type="city">Shenzhen</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Mao</surname><given-names>Renbo</given-names></name><role specific-use="author">Author</role><aff><institution>Chinese Institute for Brain Research</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Rao</surname><given-names>Yi</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wenxia</given-names></name><role specific-use="author">Author</role><aff><institution>Peking University</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><disp-quote content-type="editor-comment"><p><bold>Joint Public Review</bold></p><p>The molecular composition of synaptic vesicles (SVs) has been defined in substantial detail, but the function of many SV-resident proteins are still unknown. The present study focused on one such protein, the 'orphan' SV-resident transporter SLC6A17. By utilizing sophisticated and extensive mouse genetics and behavioral experiments, the authors provide convincing support for the notion that certain SLC6A17 variants cause intellectual disability (ID) in humans carrying such genetic variations. This is an important and novel finding. Furthermore, the authors propose, based on LCMS analyses of isolated SVs, that SLC6A17 is responsible for glutamine (Gln) transport into SVs, leading to the provocative idea that Gln functions as a neurotransmitter and that deficits in Gln transport into SVs by SLC6A17 represents a key pathogenetic mechanism in human ID patients carrying variants of the SLC6A17 gene.</p><p>This latter aspect of the present paper is not adequately supported by the experimental evidence so that the main conceptual claims of the study appear insufficiently justified at this juncture. Key weaknesses are as follows:</p><p>A) Detection of Gln, along with classical neurotransmitters such as glutamate, GABA, or ACh, in isolated SV fractions does not prove that Gln is transported into SVs by active transport. Gln is quite abundant in extracellular compartments. Its appearance in SV samples can therefore also be explained by trapping in SVs during endocytosis, presence in other - contaminating - organelles, binding to membrane surfaces, and other processes. Direct assays of Gln uptake into SVs, which have the potential to stringently test key postulates of the authors, are lacking.</p></disp-quote><p>We have conducted multiple control experiments to exclude the possibility of contamination.</p><p>1). Western blot analysis of SLC6A17-HA immunoisolation (Figure 4D and Figure 4—figure supplement 1) has shown that this faction contained little other organelles and membranes. These results are strong argument that contaminations in our isolated fraction were in very low level.</p><p>2). We then examined the proportion of SLC6A17 localized SVs through quantifying the co-localization of Syp and SLC6A17 by anti-Syp immunoisolation in Slc6a17-2A-HA-iCre mice. We found that SLC6A17 is predominately localized on SVs (with 98.7% compared with classical SV marker, Author response image 1A). This further showed that immunoisolated SLC6A17 fraction was mainly composed of SVs.</p><p>3). We also analyzed other SV marker proteins such as Syt1 and Syb2 for IP-LC-MS, all results supportedGln enrichment (Author response image 1B).</p><p>4). Importantly, immunoisolation of the SLC6A17P633R-HA protein, which caused SLC6A17 mislocalization away from the SVs (Figure 3B and Figure 3—figure supplement 1C, D), showed no Gln enrichment (Author response image 1C).</p><p>5). Moreover, immunoisolation of AAV-PHP.eb overexpressed cytoplasmic membrane Gln transporter SLC38A1-HA did not show Gln enrichment (Author response image 1D).</p><p>6). We also tested whether trafficking organelles such as the lysosome could enrich Gln. As is shown in Author response image 1E, immunoisolation of AAV-PHP.eb overexpressed TMEM192-HA did not show Gln enrichment.For active transport, we tested the effects of proton dissipator FCCP, v-ATPase inhibitor NEM and ΔpH dissipator nigercin. As is shown in Author response image 1F, 1G, Gln level was reduced by these inhibitors, supporting active transport of Gln.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Control experiments to test for contamination.</title><p>A. Anti-Syp immunoisolation in Slc6a17-2A-HA-iCre mice. B. Quantification of Gln level in anti-Syt1 and anti-Syb2 immunoisolated fraction. C. Anti-HA immunoisolation in SLC6A7-2A-HA and anti-Slc6a17P633R mice. D. Anti-HA immunoisolation in AAV-PHP.eb-hSyn-SLC38A1-HA overexperssion mice. E. Anti-HA immunoisolation in AAV-PHP.eb-hSyn-TMEM192-HA overexperssion mice. F. Anti-HA immunoisolation in SLC6A7-2A-HA mice under FCCP (50 μM) and NEM (200 μM). G. Anti-Syp immunoisolation in wild type mice under FCCP (50 μM) and Nigercin (20 μM).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>B) The authors generated multiple potentially very useful genetic tools and models. However, the validation of these models is incomplete. Most importantly, it remains unclear whether the different mutations affect SLC6A17 expression levels, subcellular localization, or the expression and trafficking of other SV and synapse components.</p></disp-quote><p>The verification of transgenic mouse line is described in the Material and Methods section of our manuscript. There are numerous literatures published for CRISPR mediated gene editing in animals and the off-target effect of CRISPR-Cas9 system is widely studied with optimized design tools developed by many groups (<xref ref-type="bibr" rid="bib83">Platt et al., 2014</xref>; Chu et al., 2015, 2016; Liu et al., 2017; Gemberling et al., 2021; Singh et al., 2022). The gRNAs used for animal generation were chosen carefully based on publically available tools. Apart from basic genomic PCR sequencing of target regions of all gene edited mouse models, Southern blots were performed by Biocytogen company for Slc6a17-HA-2A-iCre and Slc6a17P633R mice to rule out random insertions. Expression levels in Slc6a17-KO and Slc6a17P633R mice were not affected, as shown in Figure R2. HA-tagged protein in Slc6a17-HA-2A-iCre and Slc6a17P633R mice were detected by immunoisolation, immunofluorescence, and fractionation (Figure 3, 4, Figure 3—figure supplement 1, Figure 4—figure supplement 1). Both showed localizations expected from previous reports ().</p><disp-quote content-type="editor-comment"><p>C) Apart from the caveats mentioned above regarding Gln uptake into SVs, the data interpretation provided by the authors lacks stringency with respect to the biophysics of plasma membrane and SV transporters.</p></disp-quote><p>The biophysics of SLC6A17 was carefully studied (Para et al 2008; Zaia and Reimer, 2009). Our work focused on in vivo biochemical results, not biophysics.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Verification of genetic mouse models.</title><p>A. q-PCR verification of Slc6a17-KO mice; B. q-PCR verification of Slc6a17P633R mice; C. Example of genomic primer design for Slc6a17-HA-2A-iCre mice founder mice screen; D. Example of genomic PCR for Slc6a17-HA-2A-iCre mice founder mice screen; E. Southern blot performed for Slc6a17-HA-2A-iCre mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86972-sa2-fig2-v1.tif"/></fig><p>Reference</p><p>Chu, Van Trung et al. “Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells.” Nature biotechnology vol. 33,5 (2015): 543-8. doi:10.1038/nbt.3198</p><p>Chu, Van Trung, et al. &quot;Efficient generation of Rosa26 knock-in mice using CRISPR/Cas9 in C57BL/6 zygotes.&quot; BMC biotechnology 16.1 (2016): 1-15.</p><p>Gemberling, Matthew P et al. “Transgenic mice for in vivo epigenome editing with CRISPR-based systems.” Nature methods vol. 18,8 (2021): 965-974. doi:10.1038/s41592-021-01207-2</p><p>Liu, Edison T., et al. &quot;Of mice and CRISPR: The post‐CRISPR future of the mouse as a model system for the human condition.&quot; EMBO reports 18.2 (2017): 187-193.</p><p>Madisen, Linda, et al. &quot;A robust and high-throughput Cre reporting and characterization system for the whole mouse brain.&quot; Nature neuroscience 13.1 (2010): 133-140.</p><p>Parra, Leonardo A., et al. &quot;The orphan transporter Rxt1/NTT4 (SLC6A17) functions as a synaptic vesicle amino acid transporter selective for proline, glycine, leucine, and alanine.&quot; Molecular pharmacology 74.6 (2008): 15211532.</p><p>Platt, R.J., Chen, S., Zhou, Y., Yim, M.J., Swiech, L., Kempton, H.R., Dahlman, J.E., Parnas, O., Eisenhaure, T.M., Jovanovic, M., et al. (2014). CRISPR-Cas9 knockin mice for genome editing and cancer mode Yang, Hui, Haoyi Wang, and Rudolf Jaenisch. &quot;Generating genetically modified mice using CRISPR/Cas-mediated genome engineering.&quot; Nature protocols 9.8 (2014): 1956-1968.ling. Cell 159, 440-455.</p><p>Singh, Surender et al. “Opportunities and challenges with CRISPR-Cas mediated homologous recombination based precise editing in plants and animals.” Plant molecular biology, 10.1007/s11103-022-01321-5. 31 Oct. 2022, doi:10.1007/s11103-022-01321-5</p><p>Zaia, K.A., and Reimer, R.J. (2009). Synaptic vesicle protein NTT4/XT1 (SLC6A17) catalyzes Na+-coupled neutral amino acid transport. J Biol Chem 284, 8439-8448.</p></body></sub-article></article>